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 Aim of the study:  To do a detailed histopathological study of  all   Primary Lung 
Adenocarcinomas using the New IASLC/ATS/ERS classification,  biopsied in our 
institution from June 2011- December 2012 and correlate this  data with EGFR mutational 
status .  
 
Objectives: 
1.  To  categorize  and  study  the  detailed  histopathological  features  of  all  Primary  Lung   
Adenocarcinomas using   the  2011  New  International  Classification  (IASLC/ATS/ERS) 
classification for lung adenocarcinomas . 
2.  To  correlate  these  histopathological  features  with  data  available  on   EGFR  
mutational  status  performed  by  PCR  Sequencing.  
3.  To  further  sub-classify  these  adenocarcinomas  that  is  predominantly  associated with 
EGFR mutations. 
4.  To correlate the above with parameters such  as gender, age, smoking, status and stage of 
disease.   
 
Clinical and statistical methods:  
Two hundred and seventy four cases were categorized using the IASLC/ETS/ARS 
classification and correlated with EGFR exon sequences performed in a subset of 120 
cases using PCR Sequencing. TTF-1 immunohistochemistry was performed in majority of 
cases.  Demographic details including age, gender,  smoking status and  geographical 
location were obtained from  the  electronic computerized medical records.  Radiological 
findings  were obtained from the CT scan results  from the Picture Archiving and 
Communication System. 
 
Data was analyzed using the SPSS software.  Descriptive statistics for continuous data 
were  analyzed using mean with Standard deviation or median with inter-quartile range. 
Categorical data was described using frequencies and percentages. Histopathological 
subtypes, cell type and clinico-pathological features with EGFR mutational analysis were 
associated using Fischer's exact test and Chi square test. 
 
Results: The predominant biopsy categories of adenocarcinoma were, invasive acinar 
(61%), solid with mucin production (23%), mucinous (19%) and lepidic (4%). EGFR 
mutations were detected in 40.9% cases, mainly with lepidic (60%), papillary (44.4%), 
acinar (42.7%) and solid variants (41.7%) and cuboidal cell type (P=0.013) and infrequent 
with mucinous subtype (P=0.015).The commonest form of mutation involved exon 19 in 
69.4% cases. Majority were TTF-1 positive (81%, P=0.007), mainly associated with 
lepidic and papillary subtypes. The polygonal cell type was frequently noted among grade 
III tumours, in stage IV and smokers. The solid variant was relatively frequent in smokers 
and was poorly differentiated. Thus, in this study we conclude that the New  
IASLC/ATS/ERS classification confirms the positive statistical association of the 
predominant subtype of invasive adenocarcinoma and the cell type with EGFR mutations 
and TTF-1 reactivity. 
 
Keywords: New IASLC/ATS/ERS classification, Adenocarcinoma, Lung, Epidermal 
growth factor receptor, TTF-1. 
 
Introduction 
 
Lung cancer continues to be a leading cause of mortality globally. 
Worldwide it comprises 17% of the new cancer cases and 23% of the cancer 
deaths in men. The mortality burden for females in developing countries is 
similar to  cervical cancer in women, approximately 11% of the  female cancer 
deaths(1).  The 2008 GLOBOCAN reported that India had around 47,010 new 
cases of lung malignancy in males and around 11,557 new cases of lung 
malignancy in females (2) In India, it is the most  frequently diagnosed 
malignancy in  males and the 4th most common together in  both genders. 
 
Lung cancers are broadly classified based on histological features and 
response to conventional therapies  as small cell lung cancer and non small 
cell lung cancer (NSCLC), latter being the commonest (3).  Non small cell 
lung carcinoma includes three subtypes mainly, squamous cell carcinoma, 
large cell carcinoma  and adenocarcinoma and these can be further divided 
into various subtypes or variants (4) , adenocarcinoma  being  the commonest 
histological subtype of NSCLC (5)(6). Smoking is an established major risk 
factor identified in  all types of lung carcinoma, most commonly associated 
with  male smokers and squamous cell carcinoma being the histological 
predominant subtype  (7).  Adenocarcinoma  is the most common subtype in 
non smokers and  female gender, with increasing incidence rates with time.(7) 
 
1
Until recently, NSCLC was treated as a single disease with "one size 
fits all' therapeutic approach with conventional chemotherapeutic effects. Each 
subtype was found to display distinct patterns of genomic alterations with 
different response rates, toxicity and progression free survival with targeted 
drugs like bevacizumab, pemetrexed and tyrosine kinase inhibitors. (6) 
 
Lung cancers are the most histologically variable and display 
heterogeneity between cases and within individual tumours, which is 
important for pathologists reporting this tumour type. Small biopsies samples 
which form the diagnosticbulk may not be representative of the tumour.(8).  
Inspite of this heterogeneity, histology is still regarded recognized as an 
important factor in treatment selection (6)(9)(10). 
 
The world health organization (WHO)  classification in 1999,  
introduced the adenocarcinoma of the mixed subtype category, which was 
maintained in  2004  WHO classification of lung tumours, 2004(11)(12). The 
shortcoming of  WHO classification, 1999/2004 was that the mixed subtype of 
adenocarcinoma comprised 94% of cases in one of the series(13).  Inspite of 
being pathologically accurate, it is of limited clinical utility as most 
adenocarcinomas fell into this category despite  varied outcomes .(14)(15). 
The micropapillary carcinoma was not included as an independent subtype, 
which has emerged as a important poor subtype of lung adenocarcinoma 
adenocarcinoma in early-stage tumours (16,17). Besides these major flaws 
both mucinous and non- tumours were clubbed under the category of 
bronchioloalveolar carcinoma (BAC) although they have different clinical, 
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radiological, pathologic and molecular features.  In resection specimens, 
AISand  MIA  were not separately classified inspite of 100% 5 year disease 
free survival after complete resection.(18). 
 
Due to the rapidly evolving advances in the field of lung 
adenocarcinoma, there was an emergent need for improvement in histological 
categorization of lung adenocarcinomas according to prognosis as compared 
to the previous classifications. To address  various issues, in 2008  an  
multidisciplinary panel  sponsored by the International Association for the 
study of Lung Cancer (IASLC), American Thoracic Society (ATS) and 
European Respiratory Society (ERS), proposed the  new IASLC/ATS/ERS 
International  Lung Adenocarcinoma Classification,  published in 2011(19). 
This classification highlights several   paradigm shifts to overcome the pitfalls 
of the WHO 2004 classification, and to precisely diagnose and sub-classify 
lung adenocarcinomas, in view of the established relationship between 
histologic classification and predictive molecular markers. 
 
Thus, with the guidelines of the current IASLC/ETS/ARS 
classification it is possible to categorize and prognosticate lung cancers as per 
particular subtype.  In this era of personalized treatment for lungcarcinoma 
based on the histology (adenocarcinoma versus squamous) and molecular 
status (i.e., epidermal growth factor receptor [EGFR] mutation and anaplastic 
lymphoma kinase [ALK] rearrangement in adenocarcinoma), the pathologist’s 
role is vital.  There are specific treatments for patients depending on the 
histology and the molecular status of tumour.  
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Thus, we categorized and performed a detailed histopathological 
analysis of lung adenocarcinomas including poorly differentiated carcinomas 
using the current IASLC/ETS/ARS classification in an Indian cohort. 
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AIMS & OBJECTIVES 
 
Aim of the study: To do a detailed histopathological study of   all 
Primary Lung  Adenocarcinomas using the new International classification, 
biopsied in our institution from   June 2011- December 2012 and correlate this 
data with EGFR mutational status. 
 
Objectives: 
 
1. To categorize and study the detailed histopathological features of all  
Primary Lung  Adenocarcinomas including Poorly Differentiated  
Carcinomas using  the 2011 New International Classification 
(IASLC/ATS/ERS) classification for lung  adenocarcinomas . 
 
2. To correlate these histopathological features with data available on 
EGFR mutational status performed by PCR Sequencing                                                                                                                                                                                         
to further sub-classify these adenocarcinomas that is predominantly 
associated with   EGFR mutations. 
 
3. To correlate the above with parameters such as gender, age, smoking 
status and stage of disease. 
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REVIEW OF LITERATURE. 
 
Lung carcinomas display heterogeneity between cases and within 
individual tumours, with profound implications for exact histopathological 
categorization of these tumours. Approximately 70% of lung carcinomas are 
unresectable as these patients present in end stage of disease, hence small 
biopsies which form the diagnostic bulk might be unrepresentativeof the 
tumourarchitecture. (8)(20)Despite  this morphological heterogeneity, 
histology is still regarded recognized as an important factor in treatment 
selection. (6)(9)(10) 
 
Histogenetic origin of Lung Adenocarcinoma 
Lung tissue from where lung carcinomas arise are dividedanatomically 
as the air conducting system and lung parenchyma in the periphery, associated 
with gaseous exchange. TTF-1 is expressed in the periphery in small 
bronchioles and alveoli.  The peripheral bronchioloalveolar compartment 
comprisingof terminal bronchioles, alveoli and alveolar ducts are lined by 2 
potential cells of tumour origin, the type II pneumocytes  and Clara cells, 
together comprising terminal respiratory unit (TRU) that give rise to tumours 
that express TTF-1. These tumours manifest as ground glass nodules on CT. 
 
The bronchi contain the bronchial basal cells and the mucous cells, the 
potential progenitor tumour cells, giving rise to tumours that are TTF-1 
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negative and show a solid appearance on imaging.. Thus, the expression 
profile of lung adenocarcinomas includes that of TRU, and the non TRU 
adenocarcinomas, with distinct histogenetic origins. (19,21) 
 
In 2004, the World  Health Organization (WHO) classified lung 
adenocarcinomas as follows (12) 
 
 
2004 WHO HISTOLOGICAL CLASSIFICATION OF LUNG 
ADENOCARCINOMA 
Bronchioloalveolar carcinomas 
 Mucinous type 
 Non mucinous type 
 Mixed non-mucinous & mucinous or  indeterminate type 
Acinar adenocarcinomas. 
Papillary adenocarcinomas. 
Solid adenocarcinomas 
Variant 
 Fetal adenocarcinomas. 
 Mucinous cystadenocarcinomas. 
 Colloid carcinomas. 
 Signet ring adenocarcinomas 
 Clear cell adenocarcinomas. 
The  (2004)  WHO classification  categorized  bronchioloalveolar 
carcinomas (BAC) into two subtypes namely mucinous and non-mucinous 
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which have been reclassified  by the New International Classification as 
mucinous/ non mucinous Lepidic predominant adenocarcinomas 
respectively(18). 
 
Lepidic-predominant adenocarcinoma, previously known as 
bronchioloalveolar carcinoma (BAC) typically consists of bland pneumocytes 
(type II pneumocytes) that grow along surface of alveolar walls. The invasive 
adenocarcinoma component should be present in atleast 1 focus, >5mm in 
greatest dimension. The invasive component is defined as the presence of 
histologic subtypes apart from than a lepidic pattern and / presence of 
myofibroblastic stroma associated with invasive tumour cells.   A diagnosis of 
lepidic-adenocarcioma  is made in cases of MIA  if the cancer cells 
demonstrate lymphovascular invasion, invade pleura or (ii) presence of tumour 
necrosis(18) 
 
The non mucinous lepidic predominant typically shows Clara cell 
and/or type II cell differentiation. The Clara cells are columnar with 
cytoplasmic snouts and havepaleeosinophilic cytoplasm. Nuclei might be 
apical in location. Type II cells are  dome-shaped or cuboidal  with fine 
cytoplasmic vacuoles or clear to foamy cytoplasm.(12). On 
immunohistochemistry these tumours are positive for TTF-I and CK7 and 
negative for CK 20. They  probably show  EGFR mutation and only 
occasionally  associated with KRAS mutations.(18) 
Invasive mucinous adenocarcinoma previously addressed as 
mucinous BAC with distinctive histological features. The cells have columnar 
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or goblet cell morphology with abundant cytoplasmic mucin with minimal or 
absent nuclear atypia. The alveoli also contain mucin. These tumours may 
show heterogeneity of lepidic, acinar, micropapillary, papillary, and solid 
growth as nonmucinous tumours. They have to be differentiated from 
adenocarcinomas producing mucin but without the goblet cell or columnar 
morphology, that resemble and have been classified as mucinous BAC.  The 
diagnosis of such tumours are suffixed with the term ‘‘with mucin 
production’’ or ‘‘with mucinous features(18) 
 
On immunohistochemistry they are positive for CK7, CK20 and 
negative for TTF-I.  The separation of these tumours is important because they 
have the most robust histological- molecular correlation with KRAS mutations 
and EGFR mutations. Metastatic mucinous adenocarcinomas from sites such 
as the pancreas and ovary can appear morphologically identical to pulmonary 
invasive mucinous adenocarcinoma(22) 
 
Pancreatic mucinous adenocarcinomas are likely to express cytokeratin 
(CK) 20 and mucin 2 (MUC2). Metastatic  colorectal adenocarcinomas often 
express caudal-related homeobox 2 (CDX-2) and CK20 with lack of CK7 (18) 
The invasive mucinous adenocarcinomas apart from having a different 
histological appearance from the non  mucinous BAC, also presents frequently 
with multiple nodules, lobar consolidation  and or bilateral lung involvement 
with frequent KRAS mutations as opposed to EGFR mutations.(19) 
Tumours with mixed mucinous and non-mucinous features are rare, if 
so, the percentages of invasive mucinous adenocarcinoma have to be 
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documented. Tumours with atleast 10% component of each mucinous and 
non- mucinous are categorized as mixed invasive mucinous and non mucinous 
adenocarcinomas.  
 
Acinar adenocarcinoma has amajority of round /oval glandular 
structures with a central luminal space, surrounded by these tumour cells. 
Neoplastic cells/ glandular spaces might demonstrate presence of  mucin.(12)  
A cribriform  pattern is also considered as a  pattern of acinar predominant 
adenocarcinoma(23) 
 
Papillaryadenocarcinoma is composed of  columnar epithelial cells 
with central fibrovascular cores. This must be differentiated from tangential 
sectioning of the alveolar walls in an area with lepidic predominant 
adenocarcinoma. A tumour with a  lepidic growth pattern, with the alveolar  
containing  papillary structures, are classified as  papillary 
adenocarcinoma(12) 
 
Micropapillary pattern comprises papillary tufts that lie within 
alveolar spaces and are enclosed within walls of connective tissue, and lack a 
fibrovascular core. The tumour cells are mostly small, cuboidal with reversed 
nuclear polarity and minimal nuclear atypia.(17).   Psammoma bodies may be 
seen. In patients with early stage micropapillary adenocarcinomas  the subtype 
be added as a major histologic subtype owing to its association with poor 
prognosis in early-stage disease(18)(17) 
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Solid adenocarcinomas comprises a predominant population of 
polygonal tumour cells arranged in sheets with no recognizable pattern. If the 
tumour is 100% solid then intracellular mucin  should be demonstrated  in 
atleast 5 tumour cells in each of 2 high power fields and confirmed by 
histochemical mucin stains.(12) 
 
Colloid adenocarcinoma has dissecting pools of mucin that contain 
islands of neoplastic epithelium. The epithelium in these  cases may be 
extremely well differentiated and sometimes tumour cells float within the 
pools of mucin.(12) 
 
Fetal adenocarcinoma comprise of glandular structures with tubules 
linedby glycogen rich, non-ciliated cells that resemble fetal lung tubules. Sub-
nuclear vacuoles are common and characteristic. Sub-nuclear and supranuclear 
glycogen vacuoles give the tumour an endometrioid appearance.(12)Majority 
are low grade with a favourable prognosis and high-grade tumours rarely 
occur.  The low-grade fetal adenocarcinomas appear to be driven by mutations 
in β-catenin,  the epithelial cells express aberrant nuclear and cytoplasmic 
staining  by immunohistochemistry(18). 
 
Entericdifferentiation can occur in lung adenocarcinomas, when >50% 
are classified as pulmonary adenocarcinomas with enteric differentiation. The 
enteric pattern  consists of tall columnar cells exhibiting  nuclear pseudo-
stratification, prominent nuclear debris and  luminal necrosis(12), sharing 
morphological and immunohistochemical features with colorectal 
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adenocarcinoma. These tumours should demonstrate atleast one marker with 
enteric differentiation (CK20, CDX- 2, or MUC2) and are consistently  
positive  with CK7 and TTF-1 in around 50% cases thus help distinguishing 
from metastatic colorectal adenocarcinoma(18). 
 
The signet ring and clear cell are regarded as cytological features and 
not as specific subtypes in the new classification since these were associated 
cytological features seen mainly in association with solid adenocarcinomas 
and also with other patterns such as acinar, micropapillary or papillary 
adenocarcinomas(18) 
 
In 1999, the World health organization (WHO)  classification 
introduced the adenocarcinoma of the mixed subtype category, which was 
retained in the 2004  WHO classification of lung tumours(11)(12)However, a 
major shortcoming of this classification was that the mixed subtype of 
adenocarcinoma comprised 94% of cases in one series.(13) Although 
pathologically accurate, it is of clinical limited utility as most 
adenocarcinomas fell into this category despite having varied 
outcomes.(14)(15) Due to the rapidly evolving advances in the field of lung 
adenocarcinoma, there was an emergent need for improvement in histological 
categorization of lung adenocarcinomas according to prognosis as compared 
to the previous classifications. 
An international multidisciplinary panel of medical oncologists, 
pathologists, respiratory physicians, surgeons, molecular biologists and 
radiologists in 2008,  sponsored by the International Association for the study 
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of Lung Cancer (IASLC), American Thoracic Society (ATS) and European 
Respiratory Society (ERS), proposed a new classification called the new 
IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma 
Classification,  published in 2011(19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IASLC/ATS/ERS Classification of Lung Adenocarcinoma in 
Resection Specimen. 
Preinvasive lesions: 
• Atypical adenomatous hyperplasia 
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• Adenocarcinoma in situ (≤ 3cm formerly BAC). 
o Non mucinous type 
o Mucinous type. 
o Mixed mucinous/non mucinous type 
• Minimally invasive adenocarcinoma (≤3cm lepidic predominant 
tumour with ≤5mm invasion) 
o Non mucinous type 
o Mucinous type. 
o Mixed mucinous/non mucinous type 
• Invasive adenocarcinomas 
o Lepidic predominant (formerly nonmucinous BAC pattern, 
with > 5mm invasion) 
o Acinar adenocarcinoma. 
o Papillary adenocarcinoma. 
o Micropapillary adenocarcinoma. 
o Solid adenocarcinoma. 
o Variants of invasive adenocarcinoma 
o Invasive mucinous adenocarcinoma (formerly mucinous BAC) 
o Colloid 
o Fetal (low and high grade) 
o Enteric. 
The new proposed classification proposed the following changes in 
resection specimens and small biopsies. (18,20) 
1) Adenocarcinoma in situ is included as a preinvasive lesion and is 
suggested for solitarytumours ≤3cm with a pure lepidic pattern and that 
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lack invasion. These tumours have a 100% disease specific survival on 
complete resection. 
2) Minimally invasive adenocarcinoma (MIA) is proposed for tumours ≤3cm 
with ≤0.5cm invasion. 
3) The term bronchioloalveolar carcinoma is discontinued, and the term 
'lepidic' is used for invasive adenocarcinomas, that have a non-invasive 
component and were previously classified as BAC. 
4) Invasive adenocarcinomas are classified on the basis of the predominant 
subtype after comprehensive histological categorization with 5% 
increments in each subtype and the mixed subtype has been discontinued. 
Comprehensive sub typing may be useful in distinguishing multiple 
primary tumours from intra-pulmonary metastasis which has great impact 
for staging of tumours. 
5) Micropapillary adenocarcinoma is added as a major subtype due to its poor 
prognosis in early stages of lung cancer.(16,17) 
6) The former mucinous BAC is now classified as invasive mucinous 
adenocarcinoma, excluding tumours that meet defined criteria for 
mucinous AIS or MIA 
7) The clear cell and signet ring adenocarcinoma subtypes are discontinued 
and are recognized as cytological changes that occur in multiple 
histological subtypes when present in any amount, however small. There is 
no recent data available to show clinical significance beyond its 
association with solid adenocarcinomas. 
8) The term mucinous cystadenocarcinoma is found to be rare and are 
classified as ' colloid adenocarcinomas with cystic change. Hence, the term 
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mucinous cystadenocarcinoma has been discontinued and included under 
the category of colloid adenocarcinoma(24) 
9) In small biopsies, the classification suggests the use of special stains 
(mucin and or immunohistochemistry) to  classify difficult cases into 
particular types, namely adenocarcinoma or squamous cell carcinoma(20) 
10) Enteric adenocarcinoma although rare, is added as  separate subtype to 
draw attention , as this adenocarcinoma shares few morphological and 
immunohistochemical features with colo-rectal adenocarcinoma.  
11) The fetal adenocarcinomas have been maintained in this classification as 
the low grade fetal adenocarcinomas are common amongst women,  occur 
in the 4th decade while the high grade fetal adenocarcinomas are most 
commonly seen in elderly male; suggesting different oncogenic 
pathways(25) 
12) To  strategically  manage  tissue  for  molecular studies. 
13) For judicious use of scanty tissue obtained in patients with lung 
adenocarcinoma, a few approaches have been mentioned for handling of 
small specimens. 
i. To cut 10-15 unstained slides, after the presence of tumour is 
confirmed, so that the block is cut only after routine haematoxylin and 
eosin staining and adequate tissue is available for 
immunohistochemistry and molecular workup. 
 
ii. The other approach is to place the biopsy cores in two separate 
cassettes for processing such that one block may be used for 
immunohistochemistry and  the other for molecular workup(20). 
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 Targeted chemotherapy based on each cell type and subtype of 
adenocarcinoma with predictive molecular markers, can thus be made 
available. 
 
Discontinue Bronchioloalveolar Carcinoma 
1. The term  BAC used by  the 1999 and 2004 WHO classifications have 
been reclassified into 5 distinct entities in resection specimens and 
include(18) 
2. Adenocarcinoma in situ. 
3. Minimally invasive adenocarcinoma. 
4. Invasive adenocarcinoma with lepidic component. 
5. Invasive mucinous adenocarcinoma, formerly called mucinous BAC. 
6. Advanced stage adenocarcinoma with a lepidic component, associated 
with a very poor survival rate. 
 
Preinvasive lesions:  
The 1999 and WHO 2004 classification recognized atypical 
adenomatous hyperplasia as a preinvasive lesion for lung adenocarcinomas. A 
major change in the current IASLC/ETS/ARS classification was addition of 
AISas ‘pre-invasive lesion' for lung adenocarcinomas in addition to previously 
known atypical adenomatous hyperplasia. Atypical adenomatous hyperplasia  
and adenocarcinoma in situ are the counterparts to squamous dysplasia and 
squamous cell carcinoma in situ respectively. 
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Atypical Adenomatous Hyperplasia : 
Atypical adenomatous hyperplasia is a localized proliferation of 
atypical type II pneumocytes measuring less than 0.5cm,  lining the alveolar 
walls and occasionally respiratory bronchioles(26,27). Gaps are present along 
the basement membrane, between cells with rounded columnar, cuboidal or 
peg shaped cells with round or oval nuclei.  Atypical adenomatous hyperplasia 
and adenocarcinoma in situ is a morphological continuum.  Differentiation 
between cellular and cytologically atypical  adenomatous hyperplasia and 
adenocarcinoma in situ may be difficult. Hence multiple characteristics 
including size, cytological and architectural features need to be evaluated(18). 
 
Adenocarcinoma in situ (AIS): 
The diagnostic criteria for adenocarcinoma in situ  as described by 
IASLC/ATS/ERS classification: 
1. Small tumours measuring ≤3 cm. 
2. Solitary adenocarcinoma. 
3. Pure lepidic.. 
4. No evidenceof stromal invasion, lymphatic, vascular or   invasion of 
pleura. 
5. No invasive component (Acinar,  solid , papillary, micropapillary, 
invasive mucinous, colloid, fetal or   enteric adenocarcinoma) 
6. Absence of intra-alveolar tumour cells. 
7. The cell type is non mucinous and rarely mucinous, occasionally 
resembling goblet cells. 
8. Absence of nuclear atypia. 
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 It was suggested that size of the tumour may be underestimated on gross 
examination, hence correlation is necessary with CT findings is important to 
determine exact tumour size. Radiologically AIS will present as a ground glass 
nodule.(18)The presence of  solid component should be examined carefully, as 
these areas  may often correlate an  invasive component.  For a diagnosis of 
mucinous adenocarcinoma in situ it is important to confirm that the lesion is 
solitary, well circumscribed and without spread in the adjacent lung 
parenchyma. 
 
Minimally invasive adenocarcinoma (MIA) 
The diagnostic criteria for MIA  as suggested by IASLC/ATS/ ERS 
classification  is (18) 
1. Small solitary  adenocarcinoma measuring,    ≤ 3cm 
2. Predominant lepidic growth pattern. 
3. Invasive component measuring   ≤5mm in greatest dimension, in any 1 
focus. The invasive component must include any histological subtype 
other than a lepidic pattern with infiltration into the 
surrounding,myofibroblastic stroma. 
4. The cell type is most commonly non mucinous and  rarely mucinous 
and occasionally resembling goblet cells . 
5. In tumours exhibiting multiple microinvasive areas, the size of the 
largest invasive area is considered, and must be ≤5mm . 
6. The diagnosis ofMIA is excluded if tumour cells exhibit 
lymphovascular or pleural invasion or contain foci of tumour necrosis.  
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 Radiologically MIA will have a majority ground glass and a solid 
component. It is important to note that the diagnosis of AIS and MIA can be 
made only, if the entire tumour is sampled. Both these tumours should be 
≤3cm in greatest dimension.(18)Most of the literature on categories of 
adenocarcinoma in situ and minimally invasive adenocarcinomas deals with 
tumours measuring  ≤2cm or 3cm and there is insufficient data to support that 
tumours measuring >3cm would qualify as MIA with 100% disease- free 
survival.  Authors suggest that these tumours should be classified as lepidic 
predominant  adenocarcinoma, with a suspicion of  AIS or MIA.(18) 
 
The criteria for AIS and MIA can be applied to multiple tumours if 
they are synchronous and not intra-pulmonary metastases. A diagnosis of 
mucinous MIA or AIS should be made with extreme caution as most tumours 
with this histologic appearance will be invasive mucinous tumours. Tumours 
diagnosed as AIS and MIA  when completely resected  have a near 100% 
disease  specific survival(18) 
 
Invasive adenocarcinomas:  
In cases of invasive adenocarcinomas, the New International 
Classification(18) suggests that  thorough  histologic subtyping should be 
done for assessments of histological types, semi-quantitatively with 5% 
increments, thus choosing a single predominant pattern   and the percentages 
of various subtypes should be reported. 
 
20
There is a hypothesis that  lung adenocarcinoma subset can  undergo a 
step wise progression from  AAH to AIS to invasive carcinomas, which may 
be a step-wise process initiated due to multiple genetic changes, responsible 
for initiation of the  malignant phenotype. (22,28)EGFRmutations, KRAS 
mutations and TTF-1 amplification are characteristic of this 
progression.(29,29) 
 
Classification for small biopsies and cytology specimens: 
70% of lung adenocarcinomas  present in advanced stages, and hence 
are diagnosed on small biopsies/ cytology specimens. Amongst the non-small 
cell lung carcinomas,most pathologists diagnose well/ moderately 
differentiated adenocarcinomas or  squamous cell carcinomas, but the 
difficulty persists with poorly differentiated tumours. Hence, these cases 10-
30% continue to be diagnosed as NSCLC-NOS(30). 
 
Over the last few years, discovery of EGFRits response to TKI has 
brought a revolution in the treatment and survival of lung adenocarcinomas.  
Patients diagnosed as adenocarcinoma or non-small cell carcinoma NOS are 
eligible for treatment with  tyrosine kinase inhibitors .  On the contrary, when 
patients having squamous cell carcinomas who were treated by bevacizumab, 
developed life threatening  haemorrhage.  Hence it is important to eliminate a 
diagnosis of squamous cell carcinoma to determine eligibility  of patients for 
treatment with TKI's (30). 
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The IASLC/ATS/ERS classification  for the first time standardized 
terminology for lung cancer in biopsies and cytology (20) This group 
suggested a limited diagnostic workup in order to preserve as much  preserve 
tissue for molecular testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of WHO 2004 classification and the IASLC/ATS/ERS 
classification for small biopsies and cytology specimens in lung 
adenocarcinomas(30) 
2004 WHO Classification Small biopsy/Cytology: IASLC/ATS/ERS 
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Adenocarcinoma 
Mixed subtype 
Papillary 
Solid 
Acinar 
 
Adenocarcinoma, describe patterns present 
Micropapillary subtype included. 
If pure lepidic pattern, add comment: 
Invasive component cannot be excluded) 
 
Bronchioloalveolar carcinoma. 
(Non mucinous) 
 
Adenocarcinoma with lepidic pattern ( If 
purely lepidic add note stating that invasive 
component cannot be excluded) 
 
Bronchioloalveolar 
carcinoma(Mucinous) 
 
Invasive mucinous adenocarcinoma 
(describe patterns present). 
 
Mucinous (colloid) 
 
Adenocarcinoma with colloid pattern. 
 
Fetal  
 
Adenocarcinoma with fetal pattern. 
 
Clear cells 
 
Adenocarcinoma  with clear cell features 
(describe patterns) 
 
Signet ring 
Adenocarcinoma with signet ring cell 
features ( describe patterns present) 
 
No 2004 WHO counterpart- 
most solid adenocarcinomas 
 
Morphologic patterns not present- supported 
by special stainsNSCLC, favour 
adenocarcinoma. 
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 Squamous cell carcinoma  
 
Morphologic patterns present : Squamous 
cell carcinoma. 
 
No WHO 2004 counterpart 
 
NSCLC, favour squamous cell carcinoma 
(by special stains) 
 
Adenosquamous carcinoma. 
 
Morphologic adenocarcinoma and squamous 
cell differentiation present 
NSCLC with adenocarcinoma  and 
squamous differentiation. 
Adeno-squamous carcinoma is a possibility. 
 
No counterpart in WHO 2004 
 
Morphologic patterns of adenosquamous not 
present, immunostain favour glandular and 
adenocarcinoma pattern 
NSCLC, NOS. 
 
 
 
Unlike the previous 2004 WHO classification where H&E stain was 
alone required ,  the IASLC/ATS/ERS classification advocates  the use of 
special stains (mucin and immunohistochemistry) for exact  sub typing of 
tumours. 
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The IASLC/ATS/ERS classification (20) proposed that  the Non-Small 
Cell Carcinoma (NSCLC) should be further classified as a more specific 
histologic subtype,  adenocarcinoma or squamous cell carcinoma in small 
biopsies and cytology specimens.    
 
When clear squamous or adenocarcinoma differentiation is present by 
morphologic criteria, an established diagnosis of adenocarcinoma or squamous 
cell carcinoma can be made. It is important to specify if the diagnosis was 
made on solely on light microscopy or with the aid of special stains (mucin 
stains /TTF-1/p63).  It is also vital  to preserve maximum  tissue for molecular 
studies(20) 
 
In NSCLC-NOS lacking  morphologic criteria, for adenocarcinoma or 
squamous cell carcinoma,  mucin stains or immunohistochemical markers 
(TTF-1/p40 or p63) may aid in making the diagnosis.   The authors suggest 
that TTF-1 may be a single value added marker serving both as a pneumocytic 
marker and marker for primary lung adenocarcinomas, being positive in 75-
85% cases.  p63 is reported as a valuable  marker for squamous 
histomorphology.  CK7 also stains more cases of adenocarcinoma than 
squamous cell carcinoma.  
Cases positive for mucin stains (PASD) and or adenocarcinoma marker 
(TTF-1) are classified as NSCLC, favour adenocarcinoma. 
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Tumours positive for squamous markers with moderate and diffuse 
staining and negative for TTF-1 are classified as NSCLC, favour squamous 
cell carcinoma. 
 
20%-30% adenocarcinomas  are known to display patchy or weak 
positivity for p63 and  have been misinterpreted to favour squamous cell 
differentiation (31).  However, staining patterns for TTF-1 and p63 are 
mutually exclusive, hence TTF-1 positive tumours are classified as NSCLC, 
favour adenocarcinoma histology, inspite of the expressionof squamous 
immunohistochemical markers.  Recently polyclonal p40 is demonstrated to 
be a more specific marker as compared to monoclonal p63, with no overlap 
with cases of adenocarcinoma(32,33). Thus, studies suggest that a panel of 
TTF- 1 and p40 may help classify most cases of NSCLC-NOS. Dual 
nuclear/cytoplasmic markers such as TTF-1/ CK5/6 or p63/Napsin cocktails 
can also be used to ascertain the diagnosis. 
 
When a dual population of cells, exclusively is positive for TTF-1 or 
squamous cell markers, a diagnosis of adenosquamous carcinoma can be 
suggested, although a confirmatory diagnosis can be made only on resection 
specimen, when each component comprises atleast 10%. 
 
NSCLC-NOS:  In case of  no clear demarcation on morphology  or 
IHC(20,30). 
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In few tumours, where no differentiation is established using light 
microscopy and or immunohistochemistry, the diagnosis of NSCLC-NOS 
should be made, after cytokeratin staining is performed.  If cytokeratin is 
negative, further stains (i.e., S100, CD45, or CD31) are needed to exclude 
other tumours such as melanoma, lymphoma, malignant mesothelioma, or 
epithelioid hemangioendothelioma. 
 
Primary lung adenocarcinomas may also be TTF-1 negative, in this 
setting, additional immunohistochemistry may be performed (i.e. CDX-2, 
cytokeratin 20, estrogen receptor, or progesterone receptor) and suggest 
clinical evaluation to exclude a metastasis from other sites such as the colon or 
breast.  
 
Invasive mucinous adenocarcinomas or colloid adenocarcinomas are 
characteristically TTF-1 negative and can be CDX-2 positive, so clinical 
correlation is needed in such tumours to exclude a metastasis from other sites 
such as the pancreas or colon. 
 
The authors suggest that a clinco-pathologic correlation is important in 
cases of NSCLC-NOS.  A biopsy obtained from a female  with Asian ethnicity 
and is a non-smoker, with ground glass lesions on imaging, suggests a more 
likely diagnosis of adenocarcinoma  and  these patients are likely to be 
associated with an EGFR mutation. 
 
Distinction of adenocarcinoma from Sarcomatoid carcinomas (22) 
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A diagnosis of pleomorphic carcinoma, blastoma or carcinosarcoma is 
not made on small biopsy/cytology specimens.  Tumours displaying 
sarcomatoid features like as nuclear pleomorphism, tumour giant cells, 
spindled cell morphology are preferably diagnosedas NSCLC,   favour 
adenocarcinoma with giant cell/spindle features. If definite or squamous or 
glandular differentiation is absent(confirmed by special stains), then a 
diagnosis of poorly differentiated non-small cell carcinoma with spindle and 
or giant cells can be made. 
 
Distinction of adenocarcinomas from neuroendocrine carcinomas (30) 
A diagnosis of LCNEC is difficult to establish on core biopsies. Cases 
of NSCLC with neuroendocrine morphology (assessed with neuroendocrine 
markers: CD56, synaptophysin and chromogranin), a diagnosis suggestive of 
NSCLC, possibly large cell neuroendocrine carcinoma (LCNEC) can be made.  
Tumours otherwise diagnosed as adenocarcinoma and lacking neuroendocrine 
morphology should not be tested for neuroendocrine markers as it would not 
affect the treatment or prognosis in any way. 
 
The term AIS and MIA should not be used in diagnosis in small 
biopsies or cytology specimens. The presence of a non-invasive pattern is 
referred a lepidic. 
Histology and prognosis: 
Histopathology  remains the gold standard for diagnosing lung 
adenocarcinomas and is an independent predictor of survival in lung 
adenocarcinomas,  independent of the T or the N factor in staging for lung 
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cancer (34).  As per the WHO 2004 classification,  94% of tumours were of 
the mixed subtype, hence definite typing of tumours was not possible. Since 
each subtype has a different prognostic value, the IASLC/ ATS/ERS proposed 
a classification of lung adenocarcinomas, where the tumour was typed on the 
basis of the predominant subtype, thus helping in  prognostication of various 
subtypes.(18,20). 
 
According to the disease free survival, Yoshizawa (35) identified 3 
prognostic groups with low, intermediate and high grade clinical behaviour 
amongst stage I patients. The low grade comprising of adenocarcinoma in situ 
and minimally invasive adenocarcinoma with a 100% 5 year disease free 
survival.  The intermediate group included the nonmucinous lepidic 
predominant, acinar predominant and the papillary predominant 
adenocarcinomas with a 90%, 84 %, and 83% 5 year disease free survival 
respectively. The high grade tumours included solid subtype with mucin 
production, micropapillary, colloid and invasive mucinous and mixed 
mucinous/ non mucinous subtypes with a 5 year disease free survival of 70%, 
67%, 71% and 76% respectively. The poor prognostic group of solid, 
micropapillary, invasive mucinous adenocarcinoma and colloid predominant 
subtypes are important because patients with these tumours may be candidates 
for adjuvant therapy.(36) 
Anami et al(37) found that tumour with a lepidic component greater 
than 50% were associated with a better survival than with tumours with a 
lesser than 50% component. 
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A similar study was also done by Sicca et al(38) who also found 3 
prognostic groups as discussed above.  Several studies have shown that 
micropapillary carcinoma have a poor prognosis.(16,35)  Miyoshi et al studied 
344 patients, and histologically divided them into 2 group namely 
micropapillary (n= 139, 40%) and others (n = 205; 60%).  They found the 
micropapillary subtype was significantly more associated with lymph node 
metastasis, intrapulmonary metastases, pleural invasion and non-smoking 
status, with a significantly lower 5 year survival of  79% in contrast to 93% of 
the non-micropapillary group(17).Ohtaki et al found that patients with solid 
adenocarcinoma (SAC)  had significantly poorer prognosis than patients 
without SAC, irrespective of the SAC ratio(39). Noriko et al found that solid 
predominant adenocarcinomas showed a strong association with higher grade, 
poorly differentiated tumours having a significantly poor survival  as 
compared with tumours with moderate and well differentiation (P<0.001)   
and were associated with a poor prognosis as compared to the non-solid 
subtypes (P=0.001). These tumours also correlated with a larger tumour size 
and were common amongst smokers and  were not commonly associated with 
EGFR mutations (5) 
 
Okada and Hashimoto  et al(40)proposed a prognostic cell type 
classification, which included the  hobnail, columnar/cuboidal, polygonal, 
goblet and mixed cell types and found that it was the hobnail type which was 
significantly associated  with EGFR mutations (P<0.001), followed by mixed, 
columnar/ cuboidal, polygonal and goblet cells. The percentage of smokers 
was significantly higher amongst the cuboidal/ columnar and polygonal cells 
30
in contrast to the hobnail and the mixed cell types. The 5 year survival rate  for 
stage I, by the 5 cell classification was highest in the hobnail cell type (83%),  
followed by polygonal (80%) > columnar/ cuboidal (74%) and goblet cell 
types; amongst stage II-IV, the polygonal cell type (64%) had a better 
prognosis, followed by hobnail (41%), mixed (39%) and cuboidal/columnar 
(24%). This contrasts other studies wherein the polygonal cell type had a 
worse survival in comparison to the other cell types.   
 
Okada and Hashimoto also compared the five cell type to TTF-1  and 
found that TTF-1 positivity was ≥ 50%  and  ≤50% in 74% and 26% cases 
respectively, similar to a study by Yatabe et al  who found a positivity of  ≥ 
50%  and  ≤50%  in 72% and 28%  respectively. Okada and Hashimoto found 
that  the hobnail  cell type was consistently associated with TTF-1 positivity in 
almost all cases (99%) , mixed  cell type  (89%)  and  in  contrast  the 
cuboidal/columnar cell type (54%) and the polygonal cell type (50%). 
Considering this outcome, they developed a hypothesis that the carcinoma 
cells imitate characteristics of progenitor cells i.e. almost all hobnail cells 
develop at the terminal respiratory unit (TRU), the mixed more distal to than 
that of the terminal respiratory unit and the remainder 
(cuboidal/columnar/polygonal) develop at the junction of TTF-1 positive and 
negative bronchioles, bronchi and bronchial glands. 
Presence of individual histological features like invasion, desmoplasia, 
stromal elastosis, and lymphovascular invasion were prognostic indicators.  
Invasion has been defined as presence of acinar, papillary, micropapillary 
patterns or myofibroblastic stroma associated with invasive tumour or if the 
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tumour displays  lympho-vascular invasion, invades pleura or contains tumour 
necrosis.(19) 
 
Xu et al in his study identifiedseveral types of invasion,  i) invasion 
with areas of destruction of the alveolar pattern with relatively uniform acinar 
structures and without a desmoplastic response. ii) Invasion of orderly acini 
with associated desmoplasia comprising of reactive fibroblasts. iii) invasion  
with a desmoplastic response, compressed acinar structures or single tumour 
cells iv) Elastosis may occur in  areas of lepidic spread, being prominent in 
central scar without invasive glands .(41) However,  Noguchi et al in his study  
separated alveolar collapse with elastosis from invasion with fibroblast 
proliferation, emphasizing the good prognosis associated with the former.(42)   
The Noguchi classification reported that the absence of invasion imparted a 
benign prognosis to the tumour.  Based on the latest IASLC/ATS/ERS 
classification, it is the size of invasive component which is a cut off between 
low grade and intermediate grade tumours. (18) Tumours with less than 5 mm 
invasive component are considered well differentiated neoplasm’s and behave 
like non-invasive pure BAC's, recently described as AIS and MIA.  
 
Several studies suggest that  the  invasive tumour size is an 
independent prognostic factor, and it may be a better predictor of prognosis 
than overall tumour size in lepidic predominant tumours(43)(44).  Recently 
Xu et al(45) described invasive components of lepidic predominant tumours 
by 3 patterns, i) complex acinar papillary, defined by enlarged acini with no 
identifiable alveolar architecture, the septae between the complex patterns 
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being about the same thickness like alveolar space between lepidic growth 
(40-60mm), ii) invasion with elastosis and desmoplasia, acinar pattern  with 
open lumina and ii) invasion with desmoplasia and presence of compressed 
glands or single cell invasion.   Xu et al(45) also stated that it is not the 
amount of invasion but the type of invasion which determines prognosis. In 
their study of lepidic predominant adenocarcinomas, they found that tumours 
in the absence of lymphovascular invasion, solid or single cell invasion had a 
good prognosis inspite of a large invasive area, including an elastotic scar.  
Invasion with desmoplasia with compressed and single cell growth is 
associated with worse prognosis compared with other patterns of invasion(45).  
 
Noriko Motoi found that there was a strong correlation of survival with 
stage and grade. 5 year survival was 81%, 62%, 0% respectively in stage I, II 
and III respectively (P<0.001). The 5 year survival of these patients with 
poorly differentiation tumours showed 37% 5year survival compared with 
84% in well or moderately differentiated tumours. (<0.001). (5) A study by 
Yoshizawa et al showed that higher stage,male gender, necrosis, poor 
differentiation and vascular invasion were all associated with worse disease-
free survival. (46) 
Epidemiologic research has found  evidence  that chronic inflammation 
can initiate or promote development of lung cancer  in conjunction with 
tobacco use .(47–49) 
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A number of studies have validated the IASLC/ARS/ETS 
classification, thus emphasizing sub typing of lung adenocarcinomas, in view 
of prognostic implications. (41,50,51) 
 
Grading of adenocarcinomas:      
In the current setting there is no well-established histologic / cytologic 
grading system for  the diagnosis  of lung adenocarcinomas. The overall grade 
is determined by the worst grade of the tumour. Recently, architectural 
patterns have suggested prognostic outcomes; poor (solid/micropapillary), 
intermediate  (papillary and acinar), favourable prognosis (non mucinous 
lepidic predominant). Hence comprehensive histologic sub typing of invasive 
tumours may will be a simple way to grade these tumours. 
 
Immunohistochemistry: 
Differentiating primary adenocarcinomas from metastatic 
adenocarcinomas in the lung can be challenging. TTF-1 is a valuable and 
favoured marker in  the diagnosis of lung adenocarcinoma, with  specificity 
and  sensitivity being positive in ~80% of primary lung adenocarcinomas(52).  
Most pulmonary adenocarcinomas have a TTF-1 positive, CK7 positive and  
CK20 negative immunophenotype. One exception is invasive mucinous 
adenocarcinomas that are TTF-1 negative, positive for CK7, frequently 
CK20and CDX-2 can be positive. Hence clinical correlation may be needed to 
exclude metastasis from pancreas, colon. (12) Metastatic adenocarcinomas 
with the exception of carcinomas of thyroid origin are negative for TTF-1. 
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Negative mucin stains and positive staining for thyroglobulin helpseparate 
metastatic thyroid carcinoma from an adenocarcinoma of the lung.   
 
Napsin is a recently developed marker for the diagnosis of primary and 
metastatic adenocarcinomas.Napsin A (Nap-A)a functional aspartic proteinase 
is a more specific and sensitive alternative for primary and metastatic lung 
adenocarcinomas.   A study by Kim et al found that the positivity and 
expression of Nap-A in metastatic lung adenocarcinomas was better as 
compared to TTF-1. In contrast there was no significant difference between 
Nap-A and TTF-1 in primary tumours of the lung. (53)Most non pulmonary 
adenocarcinomas are negative for Nap-A except, clear cell adenocarcinomas 
of the ovary, uterus and renal cell carcinomas. Thus, the combined use of Nap-
A and TTF-1  results in increased specificity and sensitivity for diagnosis  of 
primary lung adenocarcinomas(32). 
 
Polyclonal p40 is a specific marker as compared with the 
monoclonalp63 forsquamous cell malignancies without overlap 
inadenocarcinomas, suggesting that p63 may be replaced by monoclonal 
p40.(20). 
 
 
 
 
 
Epidermal growth factor receptor and mutations: 
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Lung adenocarcinomas are heterogeneous, with different pathogenesis 
in subtypes, reason being one subtype common in smokers and associated with 
KRAS mutations, the other otherbeing common in non-smokers and is 
associated with EGFR mutations. The EGFR and KRAS mutations are always 
mutually  exclusive in occurrence.(3). 
 
Lynch et al  reported that a subgroup of  cases with  non-small cell 
carcinoma , commonly with adenocarcinoma, harboured a specific activating 
mutation in the EGFR gene  that correlated with clinical response to the 
tyrosine kinase inhibitor namely Gefitinib.(54). This was subsequently 
confirmed by other investigators and showed consistently that mutations in the 
tyrosine kinase domain of epidermal growth factor receptor were more 
common amongst Asians, women, never-smokers and adenocarcinomas. 
(54)(55)(6).  These data suggest that the pathogenesis of non-small cell 
carcinoma in never-smokers could be different from the smokers. The 
development of targeted therapies, specially tyrosine kinase inhibitors, that act 
as competitive inhibitors of the ATP binding pocket and thereby block the  
downstream signalling pathway, have provided improvements in the 
therapeutic response, thus highlighting the clinical benefits of identifying and 
targeting biologically relevant alterations(6). 
 
EGFR is a transmembrane receptor tyrosine kinase protein  expressed 
in  normal epithelial, mesenchymal and neurogenic tissues.(56). It is 
associated with tumorigenesis in several malignancies including NSCLC. 
(57)(58)EGFR  belongs to the  family of  4 homologous receptors, EGFR and 
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(ERBB2-4), (59).  Although their basic structures are quite identical, each one 
has distinct properties, including variations in tyrosine kinase activity. 
 
EGFR has an extracellular ligand binding domain, a transmembrane 
portion, intracellular tyrosine kinase and regulatory domains. Upon binding of 
a specific ligand (e.g. epidermal growth factor), the normally functioning 
EGFR undergoes conformational change and phosphorylation of the 
intracellular domain occurs, leading to downstream signal transduction by 
various pathways. The tyrosine kinase receptor transmits signals of from the 
extracellular to intracellular region, thus transmitting stimuli by signal 
transduction to the nuclei. The PI3K/akt pathway,RAf/Ras/MAPK pathway 
and the JAK/STAT pathways are important signalling pathways for EGFR.  
Signal transduction causes enhancementof cell differentiation and 
proliferation. The Ras/Raf/ MAPK pathway enhances cellproliferation and cell 
survival. The P13K/Akt pathway is associated with cell growth, invasion and 
inhibits apoptosis. Hence, depending on the pathway involved , the end result 
is cell proliferation or cell maintenance by inhibition of apoptosis(60). 
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 EGFR and downstream signalling pathways 
 
The EGFR gene is over expressed in various tumours including 
tumours   from the head and neck region, lung, renal breast, colon, ovary, 
prostate, gliomas, pancreas and  bladder tumours  with good prognostic 
clinical significance for cervical, ovarian and head and neck cancers and low 
prognostic value for non-small cell lung carcinomas(60). 
 
Somatic mutations in the TK domain of EGFR are  a common feature 
observed in lung adenocarcinomas,(61) and are exploited as a therapeutic and 
prognostic tool in  treatment of lung cancers with tyrosine kinase  inhibitors 
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such as gefitinib and erlotinib, (62)(54). These drugs act by blocking the cell 
signalling as they bind to the  tyrosine kinase domain.  The presence of these 
mutations leads to activation of the signal transduction pathways, leading to 
anti-apoptosis and cell proliferation, regardless of the presence of extracellular 
ligand.  (63)  In addition to mutations in EGFR, there is evidence that 
increased EGFR gene copy number, defined as high polysomy or 
amplification is also associated with a better response to TKI's. Some cases of 
adenocarcinoma may show both EGFR mutations and increased gene copy 
number while others may show only one of them.  Studies have shown that 
approximately 50% of EGFR mutated cases may show an increased EGFR 
copy number, while about 75% with increased copy number have mutations. 
(56) DNA mutations in EGFR as detected by polymerase chain reaction (PCR) 
can occur in regions corresponding to the extracellular or intracellular portions 
of the protein. 
 
Although several mutations have been  found, the most activating 
mutations are found within exons 18, 19, 20 and 21 of the EGFR TK 
domain(64). Small in‑frame deletions in exon 19 around codons 746-750  and 
a point mutation (CTG to CGG) in exon 21 at base pair 2573, resulting in the 
substitution of lucine by arginine in codon 858  (L858R) makes up for 
approximately  90 % of all these mutations. (3,65). Point mutations in exon 18 
and 20 are described in about 5% of patients with non-small cell lung 
carcinoma. Several other mutations have are also  found at  lower frequencies ; 
however, their significance is not yet  deduced (66).These mutations cause 
change in the ATP binding domain, resulting in continuous activation of 
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EGFR, without ligand binding.  This affinity is down regulated by Gefitinib, a 
tyrosine kinase inhibitor so that cancer cells are susceptible to apoptosis, thus 
causing reduction in cancer size. 
 
The in-frame deletions of exon 19 are significantly more frequent in 
males, and point mutations in exon 21 occur more frequently in females(3) A 
study by Jackman et al has shown that  EGFR exon19 deletions have a longer 
survival, with Gefitinib or Erlotinib compared with those having  the L858R 
mutation (67)(68). 
 
The prevalence of  EGFR mutation data  has found to vary in ethinic 
populations  ranging from  24% to 66.3%  amongst   East Asians(69)(70)(71) 
to about 10% in the European and the North American populations.(72) The 
prevalence of EGFR in India ranges from 25.9 -51.8% 
.(73)(74)(75)EGFR mutations are found to be significantly more common in 
tumours expressing  thyroid transcription factor-1 (TTF-1), hence TTF-1 
positivity can predict higher EGFR mutation in lung 
adenocarcinomas(76)(77)(5).  
 
A correlation study between IASLC/ATS/ERS lung adenocarcinoma 
classification and molecular changes revealed that EGFRmutations are 
associated with a high frequency of AIS,  MIA ,  lepidic predominant  and 
papillary predominant subtypes (85.7% AIS, 83.3% MIA, 71.4% lepidic, and 
68.5% papillary), followed by acinar (38.4%) and micropapillary (40.1%) 
predominant subtypes; whereas they were uncommon in the solid predominant 
40
and mucinous BAC subtype(78)(79). (80–82) Motoi N et al found that the 
presence of  papillary and micropapillary adenocarcinomas strongly correlated 
with EGFR mutations (P<0.001). (5) The study also found that majority cases 
of major solid subtype, lacked EGFR mutations (P=0.01)  A few studies have 
reported intratumoural heterogeneity  of EGFR mutations(83)(84) A 
comprehensive study by Yatabe et al (85) suggested that intratumoral 
heterogeneity of EGFRmutations is very rare, and pseudo heterogeneity is s 
due to a combined cause of   mutant allele-specific imbalance and 
heterogeneously distributed EGFRamplification. 
 
The current recommendation for candidates eligible for EGFR mutation 
testing and treatment with TKI’s are patients diagnosed as:  
1. Adenocarcinoma 
2. Non-small cell carcinoma, favour adenocarcinoma. 
3. Non-small cell carcinoma- NOS.  
 
Studies have shown that adenocarcinomas with EGFR mutational 
analysis have a better overall survival as compared to those without them. 
(86,87). Hence, when the diagnosis is equivocal, pathologists must be aware 
that a diagnosis of squamous cell carcinoma / NSCLC, favour squamous cell 
carcinoma will exclude these patients from molecular testing and targeted 
chemotherapy.  In these circumstances, it is best to favour a diagnosis of 
NSCLC-NOS, thus making the patient eligible for targeted therapy. 
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Primary tumours or metastatic lesions are equally suitable for EGFR 
testing.  Amongst patients with multiple or apparently separate primary lung 
adenocarcinomas, each tumour may be individually tested and  testing of 
multiple different areas within a single tumour is not necessary (88). 
 
The presence of an EGFR sensitizing mutation is the biomarker most 
strongly associated with progression-free survival benefit from first-line 
EGFR TKI treatment over chemotherapy.  However, these patients with 
EGFR-mutant lung adenocarcinoma develop progression of disease on TKI 
therapy after a median of 10 to 16 months and condition has been described as 
"acquired resistance"(89).  In approximately half of the cases, tumour cells 
obtained after disease progression contain a second site mutation in the EGFR 
kinase domain The most common ( >90%) lesion involves a C →T change at 
nucleotide 2369 in exon 20, which substitutes methionine  for threonine at 
position 790 (T790M).(90). 
 
A number of theories have emerged as to how tumour cells with the 
T790M mutation emerge within TKI treatment. Sub clones bearing may arise 
de novo, while on treatment. Crystal structure modelling has  demonstrated  
that residue T790 is located in the ATP-binding pocket of the catalytic region 
of EGFR, and is  critical for the binding of  TKI'S.(91)  However, based on 
similar studies in Chronic myelogenous leukaemia, it is a possibility that in 
cases of  NSCLC sub clones bearing this secondary mutation pre-exist within 
the primary tumour clone in individual patients, however at low frequencies 
(61). 
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 Gefitinib-sensitive lung cancers are known to develop resistance dueto 
focal amplification of the MET proto-oncogene. Amplification of MET causes 
resistance by driving the ERBB3 (HER3)–dependent activation of PI3K 
pathway which is   specific to the EGFR/ERBB family receptor.  Hence,  MET 
amplification is an example of the  resistance mechanism characterized by 
gene amplification of a kinase that is not a direct or downstream target of 
Gefitinib or Erlotinib (92). 
 
Irreversible EGFR inhibitors, which are currently under clinical 
development as treatment for patients whose tumours have developed acquired 
resistance to gefitinib and erlotinib, may be ineffective in the subset of 
tumours with a MET amplification even if they contain an EGFR T790M 
mutation. Therefore, combination therapies with MET kinase inhibitors, which 
are in early-stage clinical trials, and irreversible EGFR inhibitors should be 
considered for patients whose  tumours have become resistant to gefitinib or 
erlotinib.(92) Notably, a small percentage of NSCLCs from EGFR TKI–naïve 
patients have been reported to contain both an EGFR-activating mutation and 
MET amplification(93)(94). This situation is analogous to the observation that 
untreated NSCLCs occasionally have an EGFR T790M. These concurrent 
genetic alterations may help explain why some NSCLCs with EGFR-
activating mutations fail to respond when initially treated with gefitinib (95). 
 
Phase 3 trials on patients with lung adenocarcinomas / adenocarcinoma 
component found that patients with EGFR mutations have better treatment 
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outcomes when treated with TKI’s than with conventional platinum based 
chemotherapy.  A study at our centre, by Bhat et al  found that patients with a 
positive EGFR mutational status showed a better progression  free survival in 
those who received both chemotherapy followed by TKI as  compared with 
the EGFR positive subset who received only TKI's.   Thus, this study supports 
the concept of maintenance therapy in an Indian cohort (73). 
 
Thus  multiple phase  2 clinical trials have found that   EGFR 
mutations are predictive of the beneficial response to TKI and have a 
progression free survival(30). 
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Histologic subtypes of lung  adenocarcinoma with  molecular and 
radiological correlation(22) 
SUBTYPE MOLECULAR FEATURES CT SCAN 
 
Non mucinous AIS 
and MIA 
TTF-1 + (100%) 
EGFR mutations and never smokers (10-
30%) 
KRAS mutations and smoker (10-30%) 
 
GGN, solid 
nodule 
 
Lepidic (non 
mucinous) 
TTF-1 + (100%) 
EGFR non-smokers (10-30%) 
KRAS mutation, smokers (10%) 
BRAF-5% 
 
GGN with solid 
nodule or solid 
nodule 
 
Acinar 
TTF-1 positive or negative. 
KRAS mutation smokers (20%) 
EGFR mutations <10% non-smokers. 
EML4/ALK translocation >5% 
 
Solid nodule 
 
Solid 
TTF-1 positive (70%) 
KRAS mutationand smokers (10-30%) 
EGFR mutations in non-smokers (10-
30%) 
EGFR  with amplification 20-50% 
MUC1 positive 
EML4/ALK fusion gene>5% 
P53: 50%. 
 
 
 
Solid 
45
 Papillary 
TTF-1 positive (90-100%) 
EGFR mutation: 10-30% 
KRAS- lack KRAS (3%) 
ERBB2-3% 
P53- 30%. 
 
Solid nodule 
 
Micropapillary 
KRAS mutations (33%)  
EGFR mutations (20%) 
BRAF mutations (20%) 
 
Not known 
 
Invasive mucinous 
adenocarcinoma 
TTF-1 rare positive (0-33%) 
KRAS 80-100% 
Negative for EGFR mutations. 
Muc2+ Muc5+ Muc 6+ 
 
Consolidation 
 
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) 
mutations: 
KRAS mutations are reported in 8-30% by various clinical trials in 
cases of non-small cell lung cancers(3) Activation of KRAS mutations leads to 
initiation of MAPK pathway thus regulating cell proliferation and apoptosis.  
The PI3K pathway regulates cell survival and anti-apoptotic responses. 
Majority of KRAS mutations are found in codons 12 and 13.  KRAS 
mutations are commonly seen amongst smokers/ asbestos exposure, non-
Asians and invasive mucinous adenocarcinomas. The solid predominant 
subtype has also found to be associated with KRAS mutations  Patients with 
KRAS mutations may not derive benefit from TKI'S or platinum based 
chemotherapy. The presence of EGFR and KRAS mutations is mutually 
46
exclusive. EGFR or KRAS negative tumours may have  EML4-ALK 
mutation(3) 
 
Lung cancers with ALK translocation (Human Echinoderm 
Microtubule- Associated Protein-Like-4- Anaplastic ymphoma 
Kinase). 
The EML4/ALK translocation has been recently identified as a 
predictive biomarker in patients with NSCLC, leading to oncogenic 
constitutive activation of ALK.  A minority of these tumours harbour a 
inversion in chromosome 2p, giving rise to the EML4-ALKfusion gene.  
There are no activating mutations in this fusion gene, dimerization of the 
fusion protein is the cause for its activation.  The ALK mutations have an 
intrinsic tyrosine kinase activity with downstream signalling independent of 
EGFR mutations.  ALK translocations occur in approximately 5% of lung 
carcinomas, adenocarcinomas. Young men, light ornon-smokers and an 
advanced stage of disease  may identify a population at risk to harbour this 
translocation.  ALK rearrangements are seen with solid histology with signet 
ring cells among the western population (3)Tumours with EML4-ALK 
mutation are TTF-1 positive  and may also be positive for p63.  Tumours with 
EML4-ALK mutations are found to be mutually exclusive with KRAS and 
EGFR mutations.  Denovo resistance is also known to develop in the  domain 
of the EML4-ALK fusion gene, reported during the treatment with ALK 
inhibitor .(96) 
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Vascular Endothelial Growth Factor: 
Angiogenesis is an important patho-physiologic event required for 
tumour growth and survival.  The VGEF signalling pathway important in 
vascular permeability, endothelial cell migration, proliferation and cell 
survival.  VEGF is strongly expressed in  NSCLC and correlates with 
increased microvascular density and poor clinical outcome(3). 
 
ROS-1 rearrangements:  
Recently ROS-1 rearrangement has been found in approximately 1.7% 
if lung adenocarcinomas, with effective targeted molecular therapy. These are 
mutually exclusive with ALK rearrangements, seen amongst the young, never 
smokers and adenocarcinomas. However, there has been no particular 
histologic subtype found in association with it (3,20) 
 
BRAF mutations: 
BRAF gene mutations are also seen in lung adenocarcinoma.  BRAF a 
member of the Ras/MAP kinase pathway is downstream of KRAS 
phopshorylating MEK and ERK, culminating in genes favouring proliferation 
and survival. V600E (valine to glutamate substitution) is the most common 
BRAF mutation in lung adenocarcinomas, seen in heavy smokers. 1-3% of 
BRAF mutations have been identified in lung adenocarcinomas, however 
these mutations are more common in colorectal cancers.  BRAF mutations are 
also exclusive of EGFR, KRAS and ALK mutations.(3) 
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Other rare mutations:  The PIK3CA/AKT, c- Met,  KIF5B-RET fusions and 
Her2neu are rare mutations associated with non-small cell carcinomas(3) 
 
Pyrosequencing: 
The direct DNA sequencing is the most common and conventional 
method for detection and identification of mutations in tumours. However, for 
the test to be reliable the mutant DNA must comprise atleast 20% DNA.  
Pyrosequencing is a non-electrophoretic real time sequencing technology with 
luminometric detection. 
 
Pyrosequencing has the following advantages over Sanger sequencing: 
1. The pyrosequencing technique has higher sensitivity. 
2. The Sanger sequencing technique needs greater than 20% tumour 
volume for a reliable result, whereas a tumour load of 5% would 
suffice for pyrosequencing. Hence, pyrosequencing has higher 
sensitivity. 
3. Pyrosequencing is much faster and cost effective than the Sanger 
Sequencing. 
4. However, the disadvantages for pyrosequencing are that data analysis 
may be complex at times and it can sequence only a short length of 
nucleotide sequence(97). 
 
Studies have validated the new International classification and 
confirmed the prognostic value  amongst histological subtypes of lung 
adenocarcinoma, including the low grade AIS, MIA, lepidic predominant and 
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the intermediate grade acinar and papillary adenocarcinomas, high grade 
included invasive mucinous, solid, colloid, micropapillary 
adenocarcinomas(51,98). 
 
In this era of personalized treatment a relationship has been established 
between histological  types of lung adenocarcinoma and EGFR mutational 
status. Thus, histopathological sub typing of tumours according to the new 
classification is a potential way to stratify patients  according to prognostic 
significance and  specify treatments for targeted therapy. 
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Materials and Methods 
The study was performed in the Department of General Pathology, 
Christian Medical College, Vellore, India, approved by the Institutional 
Review Board. We evaluated a retrospective series of all Primary Lung 
Adenocarcinomas   from June 2011- December 2012 using the archival 
stained and mounted Haematoxylin and Eosin (H&E) slides and formalin 
fixed paraffin embedded blocks (FFPE).  The cases were retrieved using the 
Oracle based Pathology workstation.  Cases were categorized on the basis of 
the current classification by the International Association Society of Lung 
Cancer, American Thoracic Society and European Respiratory Society 
(IASLC/ATS/ERS)(18,20).  Retrospective data regarding the relevant history, 
clinical diagnosisand radiological  findings  were obtained from the clinical 
workstation of the institution.  EGFR mutational analysis was performed in 
Molecular Pathology Department. 
 
380 cases with a diagnosis of Primary Lung Adenocarcinomas  were 
retrieved  from  June 2011- December 2012. 
 
274 cases were included. 
106 cases were excluded due to one or more of the following reasons: 
Inclusion criteria: 
1. All cases of  Primary Lung Adenocarcinoma  biopsied in our 
institution from  June 2011- December 2013. 
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Exclusion criteria: 
1. Slides and blocks for review, referred for opinion by other hospitals or 
institutions. 
2. Inadequate tissue for definite categorization of tumour. 
3. Morphological features suggestive of large cell carcinoma and negative 
for TTF-1. 
4. Morphological features suggestive of Poorly Differentiated Carcinoma 
and negative for mucin stains and TTF and or CK7. 
5. Squamous cell carcinoma. 
 
Clinical parameters:   Demographic details including age, gender, smoking 
status and geographical location were obtained from the electronic 
computerized medical records.  
 
Radiological parameters:  Radiological findings  including tumour laterality, 
location, maximum tumour dimension, associated lymphadenopathy and stage 
were obtained from the CT scan results were obtained from the Picture 
Archiving and Communication System (PACS). 
 
Histological parameters: A detailed histopathologicalstudy was done by two 
pathologists, who were blinded to clinical outcomes. Individual features 
including the predominant cell type, presence of mucin, desmoplastic 
response, stromal elastosis, lymphovascular invasion, necrosis,  inflammatory 
response and tumour grade were studied.  The WHO 2004 grading system was 
used. Comprehensive histologic sub typing was done to assess histologic 
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patterns semi quantitatively in 5% increments, thus  choosing a single 
predominant pattern using the current IASLC/ETS/ARS classification.   These 
features were correlated with one or more immunohistochemical markers  
namely TTF-1, CK7, CK20 and BerEp4 were performed using the automated 
Ventanna system . 
 
EGFR mutational status was performed on a subset by PCR 
Sequencing and the results were correlated with final histologic diagnosis, 
clinico-pathologic parameters, including age, gender, location, smoking status 
and stage of disease.   All the patients were staged based on the American 
Joint Committee on Cancer (AJCC) TNM staging manual, 7th edition. This 
study did not include treatment strategies used and also did not include follow 
up of cases. 
 
Immunohistochemistry for TTF-1/CK7/CK20/BerEp4 
Immunohistochemistry was then performed on Formalin fixed and 
paraffin embedded tissues   ( FFPE) tissue using the monoclonal antibody in 
263 cases for TTF-1, CK7 and CK20 and BerEp4 when requested for. 
 
Protocol for automated immunostaining: 
Paraffin embedded tissue sections were cut at 4μ thickness and floated 
in poly L-lysine coated slides and incubated overnight at 37˚C. 
 
These slides were then treated with 4% milk solution for 10 minutes to 
eliminate the hydrophobic effect and give positive charge to the slides 
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Then the slide labels were bar coded and the labeled slides were loaded 
in Ventanna Benchmark XT autostainer (a fully automated immunostainer). 
 
Individual protocols have been designed in the software attached to the 
machine for each marker. Specific protocols were selected according to the 
marker (table below) 
 
A standard protocol was used for most of the markers with a minimal 
variation for few individual markers. The steps included in this protocol were 
as follows:  
 
Deparaffinization 
Liquid coverslip application. 
Heat induced antigen retrieval by treating with standard CC1 solution 
(pH patent with the company) for one hour at 90˚C. 
Then the primary antibody was added and incubated for 40 minutes @ 
37˚C. 
Then the secondary antibody (Multimer) was added and incubated for 
8 minutes. 
Finally the slides were counterstained with Haematoxylin and 
incubated for 8 minutes, followed by incubation with the bluing reagent for 4 
minutes. 
(From antigen retrieval till counterstaining, in between every step the 
slides were washed with reaction buffer. The whole process is automated). 
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Then the slides were brought to 80% alcohol (2 changes) to remove the 
liquid coverslip and then dried and mounted in DPX. 
 
A known positive control slide was added to each batch. A strong 
nuclear staining of tumour cells was considered positive. 
 
Antibody Protocol Dilution Clone Manufacturer 
TTF-1 STD 40 1:200 8G7G3-1 Dako 
CK7 STD 40 1:50 OV-TL12/30 Dako 
CK20 STD 32 1:100 KS20.8 Dako 
BerEP4 MILD 32 1:100 BerEP4 Dako 
 
 
DNA extraction, PCR amplification and DNA sequencing: 
Formalin fixed and paraffin embedded blocks of patients with Primary 
lung adenocarcinomas were retrieved from the archives of Pathology. The 
H&E sections were examined by the investigator and the Guide and the area 
with maximum tumour cellularity was identified, preferentially >50%.  The 
tumour was manually micro dissected if non-neoplastic lung parenchyma was 
identified. About 3-4, 10 µ sections were taken for DNA extraction. Extraction 
was carried out using the DNA tissue extraction kit from QIAGEN India Pvt. 
Ltd, New Delhi (described below). 
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DNA extraction: 
In a 2 ml tube, the scrapped tumour from glass slides is scrapped and 
added to 200 µl ATL buffer. 
 
20 µl Proteinase K was added to the microcentrifuge tube mixed by 
vortexing and incubated in a shaking waterbath at 560C overnight until the 
tissue was completely lysed. 
 
200µl of buffer AL was added to the sample and mixed by pulse 
vortexing for 15 seconds, followed by incubation at 700C for 10 minutes.  
 
Tubes were briefly centrifuged to remove drops from the lid.200 µl of 
100% ethanol was added to the sample and mixed by pulse vortexing for 
15seconds. After mixing, the 1.5ml microcentrifuge tube was centrifuged 
briefly to remove drops from the lid. 
 
The mixture from step 4 (including the precipitate) was carefully 
transferred to the QIAamp spin column in a 2ml collecting tube.  Cap was 
closed and centrifuged at 6000g (8000 rpm) for 1 minute. QIAamp spin 
column was then placed in a clean 2ml collecting tube and the filtrate was 
discarded. 
 
500 µl of buffer AW1 was added to QIAamp spin column without 
wetting the rim. Cap was closed and centrifuged at 6000g (8000 rpm) for 1 
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minute. QIAamp spin column was placed in a clean 2ml collection tube and 
the collecting tube containing the filtrate was discarded. 
 
500 µl of buffer AW2 was added to QIAamp spin column without 
wetting the rim, followed by centrifugation at 20000g (14000 rpm) for 3 
minutes. 
 
QIAamp spin column was placed in a clean 2ml collection tube and the 
collecting tube containing the filtrate was discarded. The spin column was 
centrifuged at full speed for 1 minute. 
 
The spin column was placed in a clean 1.5ml microcentrifuge tube and 
the collecting tube containing the collection tube was discarded. 200µl of 
buffer AE was added to the spin column, followed by incubation at room 
temperature for 5 minutes. The spin column was centrifuged at 6000g (8000 
rpm) for 1 minute. 
 
1.0µl of the DNA sample was used for quantification using the 
Nanodrop (NanoDrop technologies) and the 260/280 ratio was determined. 
Measurements were repeated twice for confirmation. 
 
If PCR was not carried out immediately, samples were stored at -700C 
and taken only just before the PCR procedure. 
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PCR amplification: The polymerase chain reaction (PCR) for four 
exons, namely 18, 19, 20 and 21 was performed using the published primer 
sequences used by Lynch et al (54).  All reactions were carried in 25μl 
volume. DNA sample and the reagents were thawed to room temperature 
before starting the reaction. Tubes were tapped and centrifuged to remove 
drops from the sides and lid. 
 
Master Mix was prepared in 0.6ml PCR tubes by mixing 2.5µl buffer, 
2 µl DNTPs (Fermentas, USA), 2µl of 20 picomoles of forward and reverse 
primers (Sigma Aldric India), 0.3µl of Taq polymerase (Takara, Japan) and 
14.2 µl of distilled water. The tubes were tapped and centrifuged to mix the 
reagents thoroughly. 
 
23 µl of the master mix was added to the respective 0.2ml PCR tubes. 
The PCR tubes were then transferred to the amplification area and 2µl of 
optimally diluted DNA containing 50-80ng of DNA was added to the 
respective PCR tubes. A non-template control (NTC) was also run with every 
batch of PCR reaction for all four exons 18, 19, 20 and 21.  2µl of distilled 
water was added to the NTC tubes. 
 
The PCR tubes were tapped and centrifuged before loading into Veriti 
thermal cycler (Applied Bio systems, USA). The following thermal cycling 
profile was followed for all PCRs: 950C for 8 min, 950C for 1 min, optimized 
anneal for 1 min, 720C for 1 min and final extension of 720C for 10 min. PCR 
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products were detected by gel electrophoresis on 2% agarose gel (SRL, Cisco 
Research laboratories, India). 
 
Once the PCR products were amplified, the product was cleaned to 
remove unwanted PCR fragments and unused reagents. The products were 
cleaned based on the principle of ultra-filtration. 15 µl of PCR product and 
85ul of sterile water were applied onto the ultra-filtration membrane of the 
wells of the pre-clean plates (Millipore/Merck, USA). 20 Hg pressure was 
applied for 10 minutes. 100µl of sterile water was then added into the well and 
20 Hg of vacuum was applied for 10 minutes. The PCR products were eluted 
out with 30µl of sterile water. 
 
The PCR product was detected using a 2 % agarose gel. Sequencing of 
both the sense and antisense strands for all 4 exons was performed with an 
automated DNA sequencer (ABI PRISM 310 genetic analyser) using the ABI 
PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied 
Bio systems, USA). Mutational analysis was performed by comparing the 
sequence with the wild type and by looking for the presence all known 
mutations in these exons. 
 
DNA Sequencing: Once good pre clean products were obtained on 
electrophoresis, sequencing of both the sense and antisense strands for all 4 
exons was set up  with an automated DNA sequencer (ABI PRISM 310 
genetic analyser) using the ABI PRISM Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Bio systems). 
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Sequencing PCR was carried at 10 µl volume. Master mix was prepared using 
1 µl of  buffer, 0.3 µl of RR mix, 5.1 µl of distilled water, 1.6 µl of 1 picomole 
of forward or reverse primers and 2 µl of optimally diluted pre clean product. 
The following thermal cycle was used for sequencing PCR: 25 
denaturationcycles for 15 sec at 960C , with  annealing at 500C for 20 sec and 
followed by extension at 600C for 4 min. 
 
Post clean-up was done using membrane based ultrafiltration using 
injection solution (Millipore/Merck, USA). 10 µl of sequence product was 
mixed with 30 µl of injection solution. 20 Hg of pressure was applied for 10 
min. Then 40 µl of injection solution was added and a vacuum of 20 Hg was 
applied for 10 minutes. Sample was eluted out with 30 µl of injection solution. 
 
Samples were loaded onto 96 well plates and sequencing was done 
with an automated DNA ABI 3130 Genetic analyser. Mutational analysis were 
performed and reported by  comparing  with the wild type and by looking for 
the presence of mutations at the respective codon. 
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Statistical analysis: 
 
Descriptive statistics for continuous data was analyzed using mean 
withStandard deviation or median with inter-quartile range. Categorical data 
was described usingFrequencies and percentages.  
 
Histopathological subtypes with EGFR mutational analysis 
wasassociated using Fischer's exact test and Chi square test.  
 
P values < 0.05 was considered statistically significant in this study. 
Data was analyzed using the Statistical Package for Social Sciences (SPSS) 
software (Windows version 16). 
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RESULTS: 
The study included 274 patients with Primary lung adenocarcinomas.  
Majority patients were males 67.88 % (n=186) and 32.12% (n=88) were 
females with the mean age being 58 and 55 years respectively. Although our 
cohorts were mainly from the East 148/274 (54%) and Southern parts of India 
93/274(33.90%), the demography did not yield any significant results (P 
=0.254). A minority of patients were from the North 6(2.2%), West 2(2.2%) 
and 25(9.1%) from foreign countries mainly Bangladesh (Figure 1). 
 
 
Figure 1.  Geographical distribution of patients with lung 
adenocarcinoma 
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Majority  patients were non smokers, comprising 117/165(70.9%) and 
48(29.1%)  smokers (Figure 2) 
 
Figure 2.  Distribution of smokers and  non-smokers in lung 
adenocarcinoma 
 
The commonest location of tumours was in the right lung 125 (45.6%), 
while 76(27.7%) were bilateral and 69(26.6%) were in the left lung. Although 
the right lung had a predilection for tumours in this study, the right upper and 
lower lobes were involved in equal frequencies 47/185(25.40%) and similarly 
there was no major difference between the left upper 31(16.8%) and left lower 
35(18.9%) lobes in terms of distribution. The hilum was infrequently involved   
(Figure 3) 
29.10%
70.90%
Smokers(48) Nonsmokers(117)
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 Figure 3.   Distribution of lung adenocarcinomas in the lobes of lung. 
Maximum tumour dimension was >3cm in 178/206 (86.4%) cases, 
documented on imaging (CT scan).  A significant proportion of cases were 
stage IV 195/237 (82.2 %) at diagnosis, with fewer stage III 31/237 (13.1%) 
and 11/237 (4.7%) of Stage II (Figure 4).    There were no cases of Stage I in 
this study.  216/232 (93.1%) had associated lymphadenopathy (P=0.633). 
 
Figure 4. Distribution of stage of disease in lung adenocarcinoma. 
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The current IASLC/ATS/ETS classification(18,20) was used to  
categorize biopsies by the predominant histological subtype.  Of 274 cases , 
there were acinar  predominant  adenocarcinoma 167 (61%) ,  63(23%) solid 
with mucin production,  19 (7%) invasive mucinous adenocarcinomas, 
11(4%)lepidic predominant and the lesser common subtypes  being papillary 9 
(3.30%) , two cases each of colloid (0.7%) and  poorly differentiated, non-
small  cell carcinoma (NSCLC-NOS) (0.7%) and 1 micropapillary  
adenocarcinoma (0.3%)  (Figure 5). 
 
Figure 5.  Distribution of predominant subtypes of adenocarcinoma. 
 
Of 274 cases, the predominant cell type was polygonal 160(58.40%), 
followed by columnar 69(25.2%), cuboidal 38(13.9%), signet 4(1.4%), 
hobnail 2(0.7%) and clear cell 1(0.4%) (Figure 6). 
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 Figure 6. Distribution of predominant cell type in lung adenocarcinoma. 
The papillary subtype was associated with columnar cells 7/9(77.8%)   
(P = 0.004), the solid subtype with polygonal cells 58(92%) (P=0.00), the 
invasive mucinous adenocarcinoma had predominantly columnar cells.15/19 
(79%) (P=0.00) (Table 1). 
Table 1.  Association of cell type with predominant subtype 
Cell type N (%) Columnar 
 
Cuboidal 
 
Hobnail Clear 
cell 
 
Polygo
nal 
Signet P value 
Lepidic 11(4) 4(36.4) 
 
2(18.2) - - 5(45.5) -  
Papillar
y 
 
9(3.3) 6(66.7) 
 
1(11.1) 1(11.1) - 1(11.1) 
 
- 0.003 
Micro- 
Papillar
 
 
 
 
 
1(0.3) 1(100) - - - - -  
Acinar 167(61) 42(25.2) 31(18.6) 
 
1(0.5) - 93(55.7) - - 
Solid 63(23) - 1(1.6)* 
 
- 1(1.6) 58(92) 3(4.8) 0.00 
0.001* 
Mucinou
s 
19(7) 15(79) 
 
3(15.8) - - 1(5.2) 
 
- 0.00 
Colloid 2(0.7) 1(50) - - - 1(50) -  
NSCLC-
NOS 
2(0.7) - - - - 1(50) 1(50)  
                           P values that are significant are highlighted in the table  
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Grade of differentiation was mainly poorly differentiated 151(55.1%),  
moderately differentiated 115(42%)  and well differentiated 08(2.9%)  (Figure 
7).The papillary subtype was  moderately differentiated 9/9(100%) (P=0.00) 
and the solid subtype was poorly differentiated 57/63(90.4%). In contrast, all 
the lepidic tumours were not well differentiated (Table 2). 
 
Figure 7. Association of grade of differentiation with  predominant 
subtype. 
Table 2. Association of Grade of differentiation with predominant 
subtypes. 
 
Subtypes 
 
 
N=274(%) 
Grade of differentiation 
 
Well Moderate Poor P value 
Lepidic 
 
11(4) 
 
03(27.3) 05(45.5) 03(27.3) 0.002 
Papillary 09(3.3) 
 
- 9(100) 
 
- 
 
0.00 
Acinar 167(61) 4(2.4) 77(46.10) 86(51.5)  
Solid 63(23) - 06(9.6) 
 
57(90.4) 
 
0.00 
Mucinous 19(7) 1(5.3) 16(84.2) 
 
02(10.5) 
 
0.00 
Micropapillary 01(0.3) - 1(100) - -. 
Colloid 02(0.7) - 1(50) 1(50) - 
NSCLC-NOS 02(0.7) - - 2(100)            - 
P values that are significant have been highlighted in the table 
2.90%
42%
55.10%
Well(08)
Moderate(115)
Poor (151)
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A significant percentage of tumours were associated with mucin 
production, desmoplasia, stromal elastosis, lymphovascular invasion and 
necrosis. (Table 3 ) 
 
Table 3.  Associated features with lung adenocarcinoma. 
 
Majority cases, 226/237(95.35%) were in Stage III/IV of disease.  
Lymphovascular invasion was associated with 187/226 (82.7%) cases in stage 
III/ stage IV disease (Table 4). However, a statistical significance was not 
established between presence of lymphovascular invasion and stage of disease 
(P=0.105) (Table 5). 
 
 
 
 
 
 
Associated features N Present(%) Absent(%) P value 
Mucin production 274 226(82.5) 48(17.5) 0.002 
Desmoplasia 274 267(97.4) 7(2.6) 0.016 
Stromal elastosis 274 252(92) 22(8) 0.05 
Lymphovascular invasion 274 227(82.8) 47(17.2) 0.013 
Necrosis 274 175(63.9) 99(36.1) 0.180 
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Table 4. Association of stage of disease with predominant  subtype 
 
Table 5. Correlation of  lympho-vascular invasion with stage of disease. 
Lymphovascular 
invasion 
 
N=237 (%) 
                          Stage P 
value II III IV 
      
Present 195(82.3%) 8(72.7%) 30(93.8%) 157(80.9%) 0.105 
Absent 42(17.7%) 3(27.3%) 2(6.3%) 37(19.1%)  
 
In relation to smoking status,  the papillary 7/7 (100%), micropapillary 
1/1 (100%), followed by the Lepidic predominant 4/5(80%) , acinar 75/102 ( 
73.6%) and solid 20(55.6%) subtypes were frequent in non smokers. The solid 
subtype was relatively more   frequent among  smokers 20/36 (55.6%) (P= 
Subtypes 
 
N =237(%) Stage 
II III IV 
Lepidic 
 
11(4.6) 
 
1 (9.1) 1(9.1) 9(81.8) 
Papillary 9(3.8) 
 
0 0 9(100) 
Acinar 143(60.4) 5(3.5) 17(11.9) 121(84.6) 
Solid 55(23.2) 3(5.4) 11(20) 41(74.6) 
Mucinous 16(6.8) 2(12.5) 3(18.8) 11(68.8) 
Colloid 
 
1(0.4) 0 0 1(100) 
NSCLC-NOS 1(0.4) 0 0 1(100) 
Micropapillary 1(0.4) 0 0 1(100) 
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0.05). However, there was no statistical significance established between 
smoking status and predominant subtype (Table 6). 
 
Table 6. Association of smoking status with predominant subtype. 
 
 
 
 
 
 
 
 
 
 
 
The majority cases 189/274 (69%) had a chronic inflammatory 
response, 83(30.3%) with mixed inflammatory infiltrate and 2(0.7%) with 
acute inflammation (Figure 8) with no  statistical significance between a  
particular inflammatory response and histological subtype (Table 7). 
 
 
 
 
 
Subtypes 
 
N = 
 
Smoker Non 
     Lepidic 
 
5(3) 
 
1(20) 4(80) 
Papillary 7(4.3) 
 
0 7(100) 
Acinar 102(61.8) 27(26.4) 75(73.6) 
Solid 36(21.9) 16(44.4) 20(55.6%) 
Mucinous 13(7.8) 4(30.8%) 9(69.2%) 
Micropapillary 1(0.6) 0 1(100%) 
NSCLC-NOS 1(0.6) 1(100%) 0 
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 Figure 8. Distribution of inflammatory response in lung 
adenocarcinomas. 
Table 7. Association of inflammatory response with predominant subtype 
 
 
 
Subtypes 
 
 
N =274(%) 
Inflammation 
Acute Chronic Mixed 
Lepidic 
 
11(4) 
 
0 9(81.8) 02(18.2) 
Papillary 09(3.3) 
 
0 7(77.8) 2(22.2) 
Acinar 167(61) 1(0.5) 111(66.5) 55(33) 
Solid 63(23) 0 47(74.6) 16(25.4) 
Mucinous 19(7) 0 13(68) 6(31.6) 
Micropapillary 01(0.3) 0 1(100) 0 
Colloid 2(0.7) 0 1(50) 1(50) 
NSCLC-NOS 2(0.7) 1(50) 0 1(50) 
0.70%
69%
30.30%
Acute(02) Chronic(189) Mixed(83)
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The majority of  tumours were TTF-1 positive 213/263(81%), 
including 90% lepidic predominant and the remaining less frequently,  
including two cases, each of colloid and poorly differentiated and one case of 
micropapillary carcinoma (Figure 9 , Table 8).  There was no statistical 
significance between TTF-1 immunohistochemistry and predominant subtype. 
 
Almost all cases were for positive for CK7 134/135(99.3%) and 
BerEp4 63/65 (97%). A minority of tumours were positive for CK20. 
 
Figure 9. Distribution of TTF-1 immunohistochemistry in lung 
adenocarcinomas. 
 
 
 
 
 
 
 
81%, 81%
19%, 19%
TTF-1 positive(213) TTF-1 negative(50)
72
Table 8. Association of TTF-1 immunohistochemistry with predominant 
subtypes 
Subtype N =263(%)                       TTF -1 
Positive Negative 
    Lepidic 
 
10(3.8) 
 
9(90%) 01(10%) 
Papillary 09(3.4) 
 
7(77.8) 2(22.2%) 
Acinar 161(61.2) 134(83.2) 27(16.8) 
Solid 60(22.8) 45(75) 15(25%) 
Mucinous 18(6.8) 13(72.2%) 05(27.8%) 
Micropapillary 1(0.4) 1(100%) 0 
Colloid 2(0.8) 2(100%) 0 
NSCLC-NOS 2(0.8) 2(100%) 0 
 
 
   
 
In this study we had one case with hobnail cell type positive for  TTF-1 
(100%), followed by 89%  of cuboidal cell type,  81%  of polygonal cell type 
and   76% columnar cell type which were  TTF-1 positive . There was no 
statistical significance established between cell type and TTF-1 
immunohistochemistry  (P= 0.65) (Table 9). 
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Table 9. Correlation of TTF-1 immunohistochemistry with predominant 
cell type 
 
Cell type 
 
N (%) 
TTF1 
positive 
TTF-1 
negative 
Columnar 67 50 (76) 16(24) 
Cuboidal 37 33 (89) 04 (11) 
Hobnail 01 01 (100) 0 
Clear cell 01 0 01 (100) 
Polygonal 154 125(81) 29 (19) 
Signet cell 03 03 (100) 0 
 
Of 274 cases, majority presented in advanced stage of disease at 
diagnosis, only 6 tumours underwent resection.  Amongst the 6 resection 
specimens, the invasive mucinous adenocarcinoma was the commonest 
subtype 3/6 (50%)   2 (33.3%) cases of acinar adenocarcinoma and 1 (16.7%) 
case of solid adenocarcinoma.  These tumourswere more common in the left 
lung, majority being larger than 3cm in greater dimension (hence with radio-
pathologic correlation a diagnosis of AIS, MIA was ruled out as these tumours 
had the largest dimension, >3cm.  These tumours were in stage 2/3 of disease, 
in contrast to the small biopsy specimens , predominantly in stage 4 disease 
(Table 10) 
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Table 10.Clinico-pathological details in resection specimens 
 
On gross examination:  All tumours were ill circumscribed, majority with 
infiltrative margins and presence of necrosis.  Visceral pleural invasion was 
seen in 4/6 (66.6%) tumours.  There was no gross evidence of haemorrhage 
(Table 11). 
 
Table 11. Gross findings in resection specimens 
S. 
No 
Diagnosis Circumscript
ion 
Infiltrative 
Margins 
Pleural 
Invasion 
Haemorrhage Necrosis 
       
1. Acinar Absent Present Present Absent Present 
2. Acinar Absent Present Absent Absent Present 
3. Mucinous Absent Present Present Absent Present 
4. Solid Absent Absent Absent Absent Absent 
5. Mucinous Absent Present Present Absent Present 
6. Mucinous Absent Present Present Absent Present 
 
S. No Final diagnosis Site Size Stage 
1. Acinar Left upper <3cm NA 
2 Acinar Right lower >3cm 3 
3 Mucinous Left upper >3cm 2 
4 Solid Right lower >3cm 2 
5 Mucinous Left hilar >3cm 3 
6 Mucinous Left lower >3cm 2 
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EGFR mutational analysis was performed on a subset of 120 cases by 
PCR gene sequencing and 47 (40.9%) were found to harbour a mutation in any 
one of the four exons (18, 19, 20, 21) that are known to be hotspots of 
mutations, except one case which  had a combined mutation.  The majority 
36(73.5%) were associated with exon 19 mutation with del E746-A750,as the 
commonest form and several other uncommon deletions (Figure 10). There 
were 12(24.5%) cases with exon 21 mutations, all with  L858R gene type 
mutation. There was one case (2%) with a combined exon 20 (T790M) and 21 
mutation (L858R) (Figure 11). 
 
 
Figure 10. Distribution of EGFR mutations among lung adenocarcinoma 
(Exons 18-21) 
 
73.40%
24.40%
2.04%
19(36)
21(12)
Combined mutations(1)
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 Figure 11.  Spectrum of mutations in exon 19 of EGFR. 
Table 12. Shows the prevalance of EGFR mutational status in Indian Studies, 
ranging from 25%to 51.8%. All studies showed predominance of exon 19 
mutation followed by exon 21 mutations. 
 
Table 12.Comparison of EGFR mutational status in Indian Studies. 
Mutations Present 
study 
Bhat 
et al 
Sahoo 
et al 
Veldore 
et al 
Jay 
Mehta 
Doval 
et al 
Chougule 
et al 
Norhonha 
et al 
N= 120 106 220 1036 367 166 1018 111 
% mutation 40.9% 39.6% 51.8% 40.3% 32% 25.9% 25% 35% 
Exon18 0% 2.4% 7.9% 4.5% ND 2.3% 5.8% 2.5% 
Exon 19 73.5% 76.2% 51.6% 61% 76% 51.2% 52.9% 74% 
Exon 20 2% 4.8% 13.6% 4.1% ND 4.7% 2.4% 0.5% 
Exon 21 24.5% 16.6% 26.2% 31.8% 24% 34.9% 38% 23% 
 
 
 
 
69.40%2.80%
2.80%
2.80%
8.30%
2.80%
8.30%
2.80%
E746-A750(25)
E746-T751(1)
L747-E758(1)
E746-P753insV(1)
delL747-A750(3)
delE746-S752(1)
L747-T751del(3)
L747-A749del(1)
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Wild Type Exon 19 
 
 
 
 
 
 
Exon 19- E746-A750 del 
 
                    Figure 12. Exon 19 wild type and with E746-A50 deletion 
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EXON 20- Wild  Type                                                EXON 20- T790M 
 
 
EXON 21- Wild type                  EXON 21- L858R 
 
 Figure 13. Combined mutation in exon 20(T790M) and exon 21 (L858R) 
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There was no  statistical association of EGFR mutational status with 
geographical distribution amongst patients in  this study. EGFR mutations 
were more common among women(48.1%)  than in (32.4%)  in men  and also 
more prevalent in non smokers(45.5%) than smokers (27.8%). TTF1 positivity 
was significantly associated with EGFR  mutational status (P= 0.007). 
Regression analysis of patients with mutation and TTF1 positivity  showed a 
relative risk of 4.995 (Table 13). 
 
Table 13. Correlation of EGFR mutational status with clinico-
pathological features and TTF-1 immunohistochemistry. 
 
Characteristics 
 
Cases 
examined 
N=120   (%) 
EGFR mutations P  
value 
Wild type Mutated 
Location 
North 
 
04 (3.3%) 
 
03(75%) 
 
01(25%) 
 
0.777 
 
West 2 (1.7%) 01(50%) 01(50%)  
 
East 
 
45(37.5%) 
 
30(66.7%) 
 
15(33.3%) 
 
 
South 
 
61(50.8%) 
 
34(55.7%) 
 
27(44.3%) 
 
 
Outside India 
 
8(6.7%) 
 
05(62.5%) 
 
03(37.5%) 
 
     
Gender  
68(56.7%) 
 
46(67.6%) 
 
22(32.4%) 
 
0.08 
Male 
Female 52(43.3%) 27(51.9%) 25(48.1%)  
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Characteristics 
 
Cases 
examined 
N=120   (%) 
EGFR mutations P  
value 
Wild type Mutated 
Smoking Status 
Smoker 
Non Smoker 
N=84 (%) 
18(21.4%) 
66(78.6%) 
 
 
13(72.2%) 
36(54.5%) 
 
05(27.8%) 
30(45.5%) 
 
0.517 
TTF-1 
Positive  
Negative 
N=112(%) 
96(85.7%) 
16 (14.3%) 
 
52(78.8%) 
14(21.2%) 
 
 
44(45.8%) 
02(4.3%) 
 
0.01 
 
 
A comparison of the mutational pattern with the histological subtype 
indicated that mutations were most commonly seen in Lepidic subtype 3/5 
(60%), followed by Papillary 4/9 (44.4%), Acinar 29/68 (42.7%) and 10/24 
Solid (41.7%) subtypes in decreasing frequencies. Invasive mucinous tumours 
were infrequently associated with EGFR mutations (P= 0.015) (Table 14) 
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Table 14. Comparison of EGFR mutations with predominant subtype. 
 
There was no significant statistical association of age, gender, smoking status 
and TTF-1 postivity when compared  exclusively with exon 19 and exon 21 
mutational statuses (Table 15) 
 
Table 15. Comparison of  clinico-pathological features between cases with 
exon 19 and 21 mutations . 
Characteristics N(%) Exon 19 Exon 21 P value 
Age 37 57.7±13.3 61.36±8.07 0.411 
Male 23 18(78.3) 05(21.7) 0.852 
Female 24 19(76) 06(24)  
Smoker 05 04(80) 1(20) 0.676 
Non smoker 31 22(71) 09(29)  
TTF-1 positive 45 34(75.6) 11(24.4) 0.424 
TTF-1 negative 02 2(100) -  
Subtype N= 120   (%) EGFR mutations P 
value 
 
 
 
 
Wild type 
 
 
Mutated 
Lepidic 
 
 
 
 
 
 
05 2(40%) 3(60%) 0.380 
Papillary 09 5(55.6%) 4(44.4%) 0.737 
Acinar 68 39(57.3%) 29(42.7%) 0.343 
Solid 24 14(58.3%) 10(41.7%) 1.000 
Mucinous 13 12(92.3%) 1(7.7%) 0.015 
Micropapillary 01 1(100%) - - 
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Hypothesis test summary for the above comparison 
 
 
 
 
 
We also compared the predominant cell type with EGFR mutations, 
smoking status, grade and stage. Although the polygonal cell type (44.6%) 
was most frequently associated with EGFR mutations, the cuboidal cell type 
was significantly associated with EGFR mutations (P=0.013). There was only 
one case of hobnail cell type with an EGFR mutation. The polygonal cell type 
were associated with poor differentiation (86.1%) (P=0.00) and also with 
stage4 disease (82.01%) (Table 16). 
 
Table 16. Association of predominant cell type with EGFR mutational 
status and clinico-pathological features. 
Char. N 
(%) 
Columnar Cuboidal Hobnail Clear Polygonal Signet P* 
value 
         
EGFR 
Wild 
 
73 
 
26(35.7) 
 
05(6.8) 
 
0 
 
0 
 
42(57.5) 
 
0 
 
0.013 
Mutated 47 14(29.8) 11(23.5) 1(2.1) 0 21(44.6) 0 - 
         
Smoker 48 11(23) 08(16.6) 0 1 27(60.4) 1 - 
Non 
smoker 
 
117 36(30.8) 15(12.8) 1(0.8) 0 65(55.6) 0  
Null Hypothesis                                           Test                                 Sig               Decision 
The distribution of age is the same       Independent-                  0.411           Retain null                 
across categories for exons                     samples Mann-                                   hypothesis. 
                                                                      Whitney U test 
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Stage 2 11 03(7.1) 01(9) 0 0 07(63.6) 0  
Stage3 31 08(25.8) 05(16.1) 0 0 18(58.1) 0  
Stage 4 195 51(26.2) 28(14.3) 1(0.5) 1(0.5) 112(57.4) 2  
         
Grade 
Well 
 
08 
 
06(75) 
 
01(12.5) 
 
0 
 
0 
 
01(12.5) 
 
0 
 
0.004 
Moderate 115 54(47) 29(25.3) 1(0.8) 0 30(26.1)   
Poor 151 10(6.7) 08(5.3) 0 1(0.6) 130(86.1) 2(1.3) 0.00 
 
*P values that are significant have been highlighted in the table. 
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 Fig 14. Acinar adenocarcinoma with hobnail and elastosis (H&E 400x) 
 
 
Fig 15. TTF-1 positive acinar adenocarcinoma (200x) 
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 Figure 16. Complex acinar-papillary structures (H&E, 200X) 
 
 
Figure 17. Acinar adenocarcinoma with lympho-plasmacytic infiltrates. 
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 Figure 18. Solid adenocarcinoma (H&E 200X) 
 
Figure 19. Non mucinous lepidic predominant adenocarcinoma (H&E, 
200X) 
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 Figure 20.  Adenocarcinoma with signet cell features (H&E, 400X). 
 
 
 
Figure 21. Adenocarcinoma with clear cell features (H&E, 400X) 
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 Figure 22. Gross specimen, invasive mucinous adenocarcinoma  
 
 
Figure 23. Invasive mucinous adenocarcinoma (H&E, 200X) 
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 Figure 24. Invasive mucinous adenocarcinoma (PASD 200X). 
 
 
 
Figure 25. CK 7 positive, invasive mucinous adenocarcinoma (200X) 
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 Figure 26. Papillary adenocarcinoma (H&E, 200X) 
 
 
Figure 27. Micropapillary adenocarcinoma (H&E, 200X) 
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 Figure 28. Colloid adenocarcinoma (H&E, 200X) 
 
 
Figure 29. Colloid adenocarcinoma (PASD, 200X) 
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Figure 30. Lymphovasular invasion (H&E, 400X) 
 
 
Figure 31. Stromal elastosis (H&E, 400X) 
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Discussion: 
The prevalence of EGFR mutations in this study  was 40.9% similar to 
a recent published study from our institute, Christian Medical College, 
Vellore, a tertiary care hospital in Southern India where a prevalence of 39.6% 
of EGFR mutations was reported, with favourable progression free survival 
response with chemotherapy followed by tyrosine kinase inhibitors (9).  The 
prevalence of EGFR mutations in this study was similar to a study by Veldore 
et al in an Indian cohort, who reported a prevalence of 40.3% (99). Several 
other studies from India have reported  prevalence of  EGFR mutations 
ranging from 25%- 40.3%(55,74,100,101).   A study by Sahoo et al in India, 
reported a slightly higher prevalence of EGFR mutations of 51.2%, possibly 
due to difference in methodology as this study used ARMS PCR, a more 
sensitive PCR sequencing method, than that of the present study.  (10). The 
prevalence of EGFR mutation data from East Asian population ranges from 
24% to 66.3% as EGFR mutations, being more common amongst East Asians 
(11-13) . 
 
There was a predominance of exon 19 mutations, in our analysis with 
Del E746-A750 as the commonest mutation(69.4%) and  24.4 %  exon 21 
mutations, according to literature where small in-frame deletions in exon 19 
and a point mutation  (CTG to CGG) in exon 21 make up for ~90% of all 
mutations(3,65).  We had a predominance of exon 19 mutations a subset likely 
to respond to tyrosine kinase inhibitors, according to a study by Jackman et al 
who found that EGFR exon 19 deletions have a longer survival with gefitinib 
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or erlotinib as compared with those having the L858R mutation which is an 
exon 21 deletion. (14).   
 
There were no cases with exon 18 or 20 mutation; these point 
mutations have been described in 5% of the population with non-small cell 
carcinoma. Many other mutations are also  described at low frequencies, but 
their  relevance  is not yet known(66) . There was one case with combined 
exon 20 (T790M) and exon 21 (L858R) mutations on treatment with gefitinib, 
the exon 20 (T790M) being probably "acquired resistance" after treatment 
with gefitinib.   It is well documented in literature that in approximately half 
of the cases, tumour cells obtained after disease progression contained a 
second site mutation in the EGFR kinase domain, the most common >90% 
lesion  involving C→T change at nucleotide 2369 in exon 20 that substitutes 
methionine for threonine at position 790 (T790M)(90). The present study did 
not find any significant association of exon 19, 21 with age, gender, location, 
smoking status and TTF1. 
 
EGFR mutations were significantly more common in tumours 
expressing TTF-1, hence TTF-1 positivity can be used as a predictive marker 
for EGFR mutations as published in several studies (15, 16) (17). By 
regression analysis, we found that patients that are positive for TTF-1 were 
4.995 times more likely to have an EGFR mutation. However, with this 
classification there was no statistical significance established of any particular 
subtype with TTF1 in our study. 
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In this study, EGFR mutations were most commonly seen with lepidic 
predominant (60%), followed by papillary adenocarcinomas (44.4%). 
Literature has well documented the association of lepidic predominant 
adenocarcinomas with EGFR mutations (15, 18). In a study  by Ping Li et al  
papillary adenocarcinomas were significantly associated with EGFR 
mutations(102). We had cases both of lepidic and papillary adenocarcinoma, 
predominantly associated with EGFR mutations. These observations are 
probably  explained by the "Progression model", whereby it is hypothesised 
that the non-invasive lepidic subtype, would have progressed to  the invasive 
pattern, commonly being papillary(28). A study by Motoi et al also showed 
that papillary and Micropapillary adenocarcinomas were frequently associated 
with EGFR mutations (17). However, we had only one case of Micropapillary 
adenocarcinoma which was associated with 'Wild' type mutations. EGFR 
mutations were infrequent in our patients with invasive mucinous 
adenocarcinomas as mucinous adenocarcinomas are commonly seen in 
smokers and are associated with KRAS mutations and rarely associated with 
EGFR mutations (19-21) 
 
We compared the predominant cell type with EGFR mutations, 
smoking status, grade and stage. The Cuboidal cell type was significantly 
associated with EGFR mutations (68.6%)(P= 0.013). Only one case with 
hobnail predominant subtype was associated with EGFR mutations. The 
polygonal cell type was the most common amongst smokers (60.4%) as well 
as non- smokers (55.6%), with no statistical significance. The polygonal cell 
type was also associated with grade 3 (86.1%). (P=0.00). These findings were 
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reported in a study by Okada et al who proposed a five cell type classification, 
including the hobnail,  polygonal, goblet,  columnar/Cuboidal and mixed cell 
types and found that it was the hobnail type which was significantly associated 
with EGFR mutations(P<0.001), followed by mixed, columnar/ Cuboidal, 
polygonal and goblet cells. The percentage of smokers was significantly 
higher amongst the Cuboidal/ columnar and polygonal cells in contrast to the 
hobnail and the mixed cell types (22). 
 
The five cell types (hobnail, Cuboidal/ columnar, polygonal and  
mixed subtype) were compared with TTF-1 in a study by Okada et al (103)and 
found thatthe hobnail  cell type was consistently associated with TTF-1 
positivity in almost all cases (99%) followed by the mixed  cell type  (89%) , 
the Cuboidal/columnar cell type (54%) and the polygonal cell type (50%). 
Considering this outcome, they developed a hypothesis that, the carcinoma 
cells imitate characteristics of progenitor cells i.e. almost all hobnail cells 
develop at the terminal respiratory unit (TRU) while the mixed subtype arises 
more distal to than that of the terminal respiratory unit and the remainder 
(Cuboidal/columnar/polygonal) develop at the junction of TTF-1 positive and 
negative bronchioles, bronchi and bronchial glands. We had one case with 
hobnail cell type which was TTF1 positive.   The majority 81% cases were 
TTF-1 positive across all cell types, TTF-1 being the best pneumocytic 
marker. 
 
Invasion has been defined as presence of either of acinar, papillary, 
micropapillary patterns or myofibroblastic stroma that is associated with 
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invasive tumour/ the tumour displays lympho-vascular invasion, invades 
pleura or contains tumour necrosis.(19) All cases in this study were associated 
with an invasive component, 97.4%   of these with a desmoplastic response 
and 92 % with stromal elastosis.  According to a study by Xu et al "several 
types of invasion were identified i) invasion with areas of destruction of the 
alveolar pattern with relatively uniform acinar structures and without a 
desmoplastic response. ii) Invasion of orderly acini with associated 
desmoplasia comprising of reactive fibroblasts. iii) invasion  with a 
desmoplastic response, compressed acinar structures or single tumour cells iv) 
Elastosis may occur in  areas of lepidic spread, being prominent in central scar 
without invasive glands" (41) However,  Noguchi et al in his study  "separated 
alveolar collapse with elastosis from invasion with fibroblast proliferation, 
emphasizing the good prognosis associated with the former"(42) .  The 
Noguchi classification reported that the absence of invasion imparted a benign 
prognosis to the tumour.  
 
Based on the latest IASLC/ATS/ERS classification(18,20), it is the 
size of invasive component which is a cut off between low grade and 
intermediate grade tumours.  Tumours with less than 5 mm invasive 
component are considered well differentiated neoplasm's and behave like non-
invasive pure BAC's, recently described as AIS and MIA. Several studies have 
suggested that  the  invasive tumour component is an independent prognostic 
factor, and it could be a better predictor of prognosis than overall tumour size 
in lepidic predominant tumours(43)(44). Travis et al in their study concluded 
that the invasive tumour component which is vital for measurement rather than 
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the entire tumour size with non-invasive component, thus stating if this finding 
could impact the 'T' in the next TNM classification. XU et al(45) also stated 
that it is not the amount of invasion but the type of invasion which determines 
prognosis. In their study of  lepidic predominant adenocarcinomas, they found 
that tumours in the absence of lymph vascular invasion, solid or single cell 
invasion had a good prognosis inspite of a large invasive area, including an 
elastotic scar.  Invasion with desmoplasia with compressed and single cell 
growth is associated with worse prognosis compared with other patterns of 
invasion(45). 
 
Majority were males(67.8%), (70.8%) were  in stage IV and 55.1% of 
these were poorly differentiated with impeding survival.  Lymphovascular 
invasion was  in 82.8 %  and 63.9%  had areas of necrosis in similar to a study 
by Yoshizawa et al where higher stage, male gender, necrosis, poor 
differentiation and vascular invasion all were associated with decreased 
disease-free survival. (23). 
 
Although the majority of patients in this study were non-smokers, 
adenocarcinomas, including the solid subtype were reported among smokers 
with a relatively high frequency and majority were poorly differentiated. 
Motoi et al had found that solid predominant adenocarcinomas had a strong 
correlation with high grade, poor differentiation and were associated with a 
worse survival of 34% as compared to 94% for moderate and well 
differentiated tumours(P<0.001) and were associated with poor prognosis in 
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comparison to the non-solid subtype(P=0.001) (17). The solid 
adenocarcinomas are known to be associated with KRAS mutations(3). 
 
In this study, papillary tumours were all moderately differentiated and 
the solid variant was poorly differentiated(P=0.00).  According to a study by 
Yoshizawa,(51)  tumour grade as per the WHO 2004 classification (well  
differentiated, moderately differentiated  and poorly differentiated) were  
predictors of overall survival. Survival rates have been strongly correlated 
with stage and grade by Motoi et al (17) However, in the present study we did 
not find a significant comparison between the other grades and stages. 
 
Thus, the new IASLC/ ATS/ERS classification identifies histologic 
subtypes/ cell types and its correlation with TTF-1 immunohistochemistry 
EGFR mutational status. The lepidic predominant adenocarcinomas, papillary 
adenocarcinomas were associated with EGFR mutations and were 
significantly uncommon with invasive mucinous adenocarcinoma.  
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Limitations: 
1. A major limitation of this study was that we did not include treatment 
strategies used and follow up cases.  However, this limitation can be 
overcome to a certain extent using data that was recently published 
from our centre, where the overall survival (OS) and progression free 
survival (PFS) was assessed among 106 cases with a known EGFR 
mutational profile.  
2. The subtype and the cell type have not been correlated with PFS and 
OS that would have to determine the association of the cell types from 
a prognostic standpoint. 
3. EGFR mutational analysis by PCR gene sequencing was performed 
only in a subset of patients.  
4. EGFR mutations were performed by Sanger's sequencing, which 
requires a minimum of 50% tumour cellularity, thereby limiting its 
utility among samples with lesser cellularity. 
 
On a prospective basis, treatment protocols in these patients can be 
correlated with overall survival and progression free survival. We have now 
introduced more sensitive techniques like pyrosequencing for mutational 
analysis.  We also aim to perform other mutation tests such as KRAS and 
EML4- ALK1 gene fusion for patients negative for EGFR mutations or not 
responding to treatment with TKI's.  
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Nevertheless, the study provides valuable information in the context of 
the histological patterns and the mutational status and can be used as baseline 
data for similar studies to perform on a larger scale. 
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SUMMARY &CONCLUSIONS 
A detailed histopathological analysis of Primary Lung 
adenocarcinomas was done, using the new IASLC/ATS/ERS classification in 
biopsies and resection specimens from June 2011- December 2012 and this 
data was correlated with EGFR exon sequences performed in a subset using 
PCR gene sequencing. 
 
  The following are the results of this study summarized below: 
1. The predominant categories of adenocarcinoma were, invasive acinar 
(61%), solid with mucin production (23%), invasive mucinous (19%), 
lepidic predominant (4%), papillary subtypes (3.30%) and the rare 
subtypes of  colloid (0.7%),  non small cell carcinoma- NOS (0.7%) and 
one case of micropapillary adenocarcinoma (0.3%).  There were no cases 
of the fetal adenocarcinomas and adenocarcinomas with enteric 
differentiation. 
 
2. The prevalence of EGFR mutations was 40.9%, mutations being present 
in one of the exons (18-21) detected by PCR gene sequencing (except 
one case that had a combined exon 20 and exon 21 mutation).  The 
majority, 73.5% were associated with exon 19 mutations, with delE746-
A750 gene mutation being the commonest in 69.4% cases.  24.5% cases 
were associated with exon 21 mutations, all of L858R gene type 
mutation.  
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3. EGFR mutations were seen mainly with lepidic predominant (60%) 
followedby papillary adenocarcinomas (44.4%), acinar adenocarcinomas 
(42.7%) and the solid subtype (41.7%) and were infrequent with the 
invasive mucinous subtype(P=0.015). The EGFR gene mutations were 
significantly associated with the cuboidal cells(P=0.013). EGFR 
mutations were relatively more common amongst women, non smokers 
and were significantly associated with TTF-1 positivity with a relative 
risk of 4.995. 
 
4. Majority cases of Primary lung adenocarcinomas were TTF-1 positive 
(81%,P=0.007), mainly associated with lepidic and papillary subtypes. 
 
5. On detailed histopathological analysis, the polygonal cell type was the 
commonest, frequently noted with the solid variant, stage IV disease and 
amongst smokers.  The papillary subtype was associated with columnar 
cells. 
 
6. A majority of tumours (55.1%) were poorly differentiated, 42% 
moderately differentiated and 2.9% were well differentiated. The solid 
predominant subtypes were commonly poorly differentiated (90.4%) and 
the papillary subtype was moderately differentiated (100%). 
 
7. 69% of adenocarcinomas were associated with a lympho-plasmacytic 
response; however there was no correlation between inflammatory 
response and a particular subtype. 
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8. Majority were non smokers in this cohort and the solid variant was 
relatively frequent amongst smokers. 
 
9. The right lung had a predilection for tumours (45.6%) and was bilateral.  
 
10. Majority (86.4%) tumours on imaging were greater than 3 cm in greatest 
dimension and 82.2 % were in stage IV of disease. 
 
Thus, in this study we performed a detailed histopathological study 
with clinico-pathological correlation and established a relationship between 
subtype, cell type and EGFR mutational analysis.  
 
To our knowledge, in an Indian setting several studies have established 
a prevalence of EGFR mutations with NSCLC/adenocarcinomas though none 
have established a correlation between EGFR mutational status and lung 
adenocarcinoma in context of clinico-pathological features, predominant 
subtype and cell type using the 2011 IASLC/ATS/ERS classification.   
 
Hence, we conclude that the new IASLC/ATS/ERS classification 
confirms the positive statistical association of the predominant subtype of 
invasive adenocarcinoma, cell type with EGFR mutations and TTF-1 
reactivity. 
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PROFORMA 
1. Serial no:    2. Biopsy no:   3.Age:        4. Gender :  M/F      
5. Geog  location: North/West/East/South India/others  
6.Smoking:  Smoker/Non smoker .    
Radiological Findings : 
7.Tumour laterality: Right /Left/Bilateral  8. Primary  lobe: Upper/middle 
lobe Or lower lobe. 
9.Maximum tumour : <3.0cm/ >3.0cm.        10. Associated 
lymphadenopathy:  Yes/ No. 
11. Stage of disease: Gross findings (resection specimens) 
12.Tumour size: < 3cm/>3cm.       13.Site: Upper/middle lobe or  
lower lobe. 
14. Circumscription: Absent/ Present.15.Infiltrative margins:  Absent/ 
present. 
16.Pleural involvement:  Absent/ present     17.Haemorrhage : Absent/ 
present.      
18. Necrosis: Absent/ present. 
Histopathological subtypes: 
19.BAC  : Absent/present.  If present, then Invasive lepidic 
predominent/AIS/MIA 
20. Papillary : Absent/ present.      21.Micropapillary: Absent/ 
Present.    
22. Acinar : Absent/Present.       23.Solid component: Absent/ 
Present.   
24. Colloid: Absent/Present.    25. Mucinous: Absent/Present. 
26. NSCLC-NOS: Absent/Present.    
Microscopic details. 
27.Predominant cell type: Columnar/ Cuboidal/ Hobnail/Clear 
cell/Polygonal/Signet. 
28.Associated with mucin : Yes/ No.         29.Desmoplasia : Absent/ 
Present. 
30.Stromal elastosis : Absent/Present.        31.Lymphatic permeation 
:Absent /Present. 
32. Inflammatory cell infiltrate     Acute / Chronic/ Mixed. 
33. Necrosis:  Absent/ Present.        34. Tumour grade: Well/ 
Moderate/Poorly differentiated. 
35. TTF-1 Positive/Negative.      36. CK7Positive/Negative. 
37. CK20: Positive/Negative.   38.BerEp4- Negative/ Positive. 
39.EGFR mutational analysis: Wild type/ Mutated   If  mutated which exon 
was amplified.   
40.Gene mutation associated. 
 
 
  

  
  
 
